{"content":"<li class=\"n-box-item date-title\" data-end=\"1547701199\" data-start=\"1547614800\" data-txt=\"Monday, December 23, 2019\">Wednesday, January 16, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3423716\" data-ts=\"1547683943\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CARS\" target=\"_blank\">CARS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423716-cars-complus-7-after-announcing-review-of-strategic-alternatives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cars.com +7% after announcing review of strategic alternatives</a></h4><ul><li>Cars.com (NYSE:<a href='https://seekingalpha.com/symbol/CARS' title='Cars.com Inc.'>CARS</a>) <font color=\"green\">+7.7%</font> after-hours as it says it has been <a href=\"https://seekingalpha.com/pr/17383068-cars-com-announces-review-strategic-alternatives-enhance-shareholder-value\" target=\"_blank\">exploring strategic  alternatives</a> including a potential sale of the company.</li><li>President and CEO Alex Vetter says Cars. com has delivered 12 consecutive months of traffic growth and accelerated its digital solutions strategy, and will continue to execute its strategy throughout the strategic  review process.</li><li>Shareholder Starboard Value, which owns slightly less than 10% of Cars.com, <a href=\"https://seekingalpha.com/news/3415861-cars-com-told-improve-performance-shareholder-starboard\" target=\"_blank\">last month</a> pushed the company to improve its stock performance, sell itself or make management changes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423716\" data-linked=\"Cars.com +7% after announcing review of strategic alternatives\" data-tweet=\"$CARS - Cars.com +7% after announcing review of strategic alternatives https://seekingalpha.com/news/3423716-cars-complus-7-after-announcing-review-of-strategic-alternatives?source=tweet\" data-url=\"https://seekingalpha.com/news/3423716-cars-complus-7-after-announcing-review-of-strategic-alternatives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423711\" data-ts=\"1547681386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGIX\" target=\"_blank\">CGIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423711-cancer-geneticsplus-16-on-loan-forbearance-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cancer Genetics +16% on loan forbearance deal</a></h4><ul>   <li>Nanocap firm Cancer Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a>) has <font color=\"green\">jumped 16.2%</font> on very heavy postmarket volume after filing about a <a href=\"https://seekingalpha.com/filing/4305277\" target=\"_blank\">forbearance agreement</a> with its lenders.</li>    <li>The loan amendment with Silicon Valley Bank changes the interest rate to WSJ Prime plus 2.25 percentage points (making it 6.75% at Sept. 30, 2018); sets up milestone in connection with a potential strategic transaction satisfactory to the bank; and extends the revolving line maturity to April 15, among other items.</li>    <li>A modification with Partners for Growth also sets milestones for a potential strategic transaction. That loan is an interest-only term loan of $6M bearing interest at 11.5%, maturing March 22, 2020.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3423711\" data-linked=\"Cancer Genetics +16% on loan forbearance deal\" data-tweet=\"$CGIX - Cancer Genetics +16% on loan forbearance deal https://seekingalpha.com/news/3423711-cancer-geneticsplus-16-on-loan-forbearance-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3423711-cancer-geneticsplus-16-on-loan-forbearance-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423709\" data-ts=\"1547680368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423709-amicusplus-2_7-citi-joins-bulls-on-galafold-launch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus +2.7% as Citi joins bulls on Galafold launch</a></h4><ul>   <li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) is <font color=\"green\">up 2.7%</font> after hours following an upgrade at Citi to Buy.</li>    <li>Analyst Mohit Bansal is focused on the company's Fabry disease therapy Galafold, where early indications back up a peak sales view of $1B. Some 20% of patients are starting on the capsules without switching from an existing therapy, which Bansal sees as a \"major upside\" to estimates. (h/t Bloomberg)</li>    <li>Bansal's boosted the firm's price target to $16 from $12, implying 31.6% upside from today's close.</li>    <li>Shares had closed <font color=\"green\">up 1.4%</font> to near a three-month high during the regular session.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423709\" data-linked=\"Amicus +2.7% as Citi joins bulls on Galafold launch\" data-tweet=\"$FOLD - Amicus +2.7% as Citi joins bulls on Galafold launch https://seekingalpha.com/news/3423709-amicusplus-2_7-citi-joins-bulls-on-galafold-launch?source=tweet\" data-url=\"https://seekingalpha.com/news/3423709-amicusplus-2_7-citi-joins-bulls-on-galafold-launch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423704\" data-ts=\"1547678357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTGM\" target=\"_blank\">HTGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423704-htg-molecularplus-6_2-on-new-software-for-edgeseq-suite\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HTG Molecular +6.2% on new software for EdgeSeq suite</a></h4><ul>   <li>HTG Molecular (NASDAQ:<a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a>) is <font color=\"green\">up 6.2%</font> postmarket after announcing a <a href=\"https://seekingalpha.com/pr/17382908-htg-launches-htg-edgeseq-reveal\" target=\"_blank\">new software product</a>, HTG EdgeSeq Reveal.</li>    <li>It's designed to streamline analysis of biomarket data from samples analyzed using the company's EdgeSeq Precision Immuno-Oncology Panel.</li>    <li>The software enables applications including immunophenotyping of tumor infiltrating lymphocytes; monitoring of immunotherapy response biomarkers; and the elucidation of immune-escape mechanisms known to drive disease progression, the company says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423704\" data-linked=\"HTG Molecular +6.2% on new software for EdgeSeq suite\" data-tweet=\"$HTGM - HTG Molecular +6.2% on new software for EdgeSeq suite https://seekingalpha.com/news/3423704-htg-molecularplus-6_2-on-new-software-for-edgeseq-suite?source=tweet\" data-url=\"https://seekingalpha.com/news/3423704-htg-molecularplus-6_2-on-new-software-for-edgeseq-suite\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423702\" data-ts=\"1547678137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423702-csx-acb-and-tnxp-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX, ACB and TNXP among notable after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color=\"green\">+7.7%</font>. <a href='https://seekingalpha.com/symbol/JELD' title='JELD-WEN Holding, Inc.'>JELD</a> <font color=\"green\">+4.8%</font>. <a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color=\"green\">+4.1%</font>. <a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color=\"green\">+3.8%</font>. <a href='https://seekingalpha.com/symbol/FOE' title='Ferro Corporation'>FOE</a> <font color=\"green\">+3.4%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/FUL' title='H.B. Fuller Company'>FUL</a> <font color=\"red\">-8.6%</font>. <a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"red\">-7.4%</font>. <a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color=\"red\">-3.3%</font>. <a href='https://seekingalpha.com/symbol/AGRO' title='Adecoagro S.A.'>AGRO</a> <font color=\"red\">-2.9%</font>. <a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> <font color=\"red\">-2.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423702\" data-linked=\"CSX, ACB and TNXP among notable after hour movers\" data-tweet=\"$PCG $PCG $JELD - CSX, ACB and TNXP among notable after hour movers https://seekingalpha.com/news/3423702-csx-acb-and-tnxp-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3423702-csx-acb-and-tnxp-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423685\" data-ts=\"1547675343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACB\" target=\"_blank\">ACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423685-aurora-cannabis-launches-250m-convertible-debt-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aurora Cannabis launches $250M convertible debt offering; shares down 7% after hours</a></h4><ul><li>Aurora Cannabis (NYSE:<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a>) <a href=\"https://seekingalpha.com/pr/17383009-aurora-cannabis-announces-private-offering-us-250-million-convertible-senior-notes-due-2024\" target=\"_blank\">initiates </a>an offer of $250M aggregate principal amount of convertible senior notes due 2024. Price, yield and terms have yet to be released.</li><li>Shares are down <font color=\"red\">7%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423685\" data-linked=\"Aurora Cannabis launches $250M convertible debt offering; shares down 7% after hours\" data-tweet=\"$ACB - Aurora Cannabis launches $250M convertible debt offering; shares down 7% after hours https://seekingalpha.com/news/3423685-aurora-cannabis-launches-250m-convertible-debt-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3423685-aurora-cannabis-launches-250m-convertible-debt-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>213&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423682\" data-ts=\"1547675165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423682-mannkind-debuts-afrezza-direct-purchase-program-shares-up-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MannKind debuts Afrezza direct purchase program; shares up 5% after hours</a></h4><ul><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) is up <font color=\"green\">5%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17382989-mannkind-announces-direct-purchase-insulin-program-providing-afrezza-low-4-day\" target=\"_blank\">announced program</a> allowing diabetics to purchase inhaled insulin Afrezza (insulin human) direct from the company for as little as $4 per day. Prescriptions will be filled and shipped to patients' homes by Eagle Pharmacy.</li><li>Concurrently, it has launched an enhanced copay and savings card program enabling patients to fill their prescriptions at their local pharmacy for as little as $15.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423682\" data-linked=\"MannKind debuts Afrezza direct purchase program; shares up 5% after hours\" data-tweet=\"$MNKD - MannKind debuts Afrezza direct purchase program; shares up 5% after hours https://seekingalpha.com/news/3423682-mannkind-debuts-afrezza-direct-purchase-program-shares-up-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3423682-mannkind-debuts-afrezza-direct-purchase-program-shares-up-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423664\" data-ts=\"1547674200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MHLD\" target=\"_blank\">MHLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423664-maiden-holdings-sells-european-automotive-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maiden Holdings sells European automotive group</a></h4><ul><li>Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>) <font color=\"green\">rises 3.1%</font> in after-hours trading after <a href=\"https://seekingalpha.com/pr/17382954-maiden-holdings-announces-sale-european-automotive-group-allianz-partners\" target=\"_blank\">announcing the sale</a> of AVS Automotive VersicherungsService GmbH and related European subsidiaries to Allianz Partners as part of Maiden's strategic review.</li><li>Proceeds from the sale include an undisclosed cash payment at closing and a three-year quota share reinsurance agreement with Allianz.</li><li>Maiden's AVS works with German and Austrian auto retailers, OEM, and related credit providers to design and distribute auto dealer and consumer insurance products.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420446-maiden-holdings-return-700m-unearned-premium-amtrust\" target=\"_blank\">Maiden Holdings to return about $700M unearned premium to AmTrust</a> (Jan. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3423664\" data-linked=\"Maiden Holdings sells European automotive group\" data-tweet=\"$MHLD - Maiden Holdings sells European automotive group https://seekingalpha.com/news/3423664-maiden-holdings-sells-european-automotive-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3423664-maiden-holdings-sells-european-automotive-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423643\" data-ts=\"1547672821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRTX\" target=\"_blank\">MRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423643-mirati-readies-75m-stock-offering-shares-down-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mirati readies $75M stock offering; shares down 5% after hours</a></h4><ul><li>Mirati Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a>) is down <font color=\"red\">5%</font> after hours in response to its announced <a href=\"https://seekingalpha.com/pr/17382888-mirati-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">$75M public offering</a> of common stock. Price, volume and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423643\" data-linked=\"Mirati readies $75M stock offering; shares down 5% after hours\" data-tweet=\"$MRTX - Mirati readies $75M stock offering; shares down 5% after hours https://seekingalpha.com/news/3423643-mirati-readies-75m-stock-offering-shares-down-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3423643-mirati-readies-75m-stock-offering-shares-down-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423632\" data-ts=\"1547671413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IAG\" target=\"_blank\">IAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423632-iamgoldminus-10-sees-lower-production-higher-costs-in-2019\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iamgold -10% as it sees lower production, higher costs in 2019</a></h4><ul><li>Iamgold (<a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color=\"red\">-10.6%</font>) plunges after saying it expects to <a href=\"http://www.mining.com/iamgold-expects-lower-production-higher-costs-2019/\" target=\"_blank\">produce fewer gold ounces while incurring higher costs</a> in 2019.</li><li>IAG says it produced 882K oz. of attributable oz. in 2018, at the higher end of its guidance of 850K-900K oz., but it expects all-in sustaining costs to come in near the high end of full-year guidance of $990-$1,070/oz. sold.</li><li>IAG also expects to produce fewer gold ounces in 2019, with attributable production of 810K-870K oz., at all-in sustaining costs of $1,030-$1,080 per oz., although output is seen rising while costs decline during H2 as the Saramacca mine comes online.</li><li>The company says it plans to spend $60M on exploration in 2019, down from $81M in 2018.</li><li>Separately, IAG says it will <a href=\"https://seekingalpha.com/pr/17381558-iamgold-enters-170-million-gold-prepay-arrangement\" target=\"_blank\">receive  $170M</a> from a syndicate of financial institutions  in exchange  for delivery of 150K oz. of gold in  2022, with provisions to receive additional payments  if the gold price is above $1,300/oz.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423632\" data-linked=\"Iamgold -10% as it sees lower production, higher costs in 2019\" data-tweet=\"$IAG - Iamgold -10% as it sees lower production, higher costs in 2019 https://seekingalpha.com/news/3423632-iamgoldminus-10-sees-lower-production-higher-costs-in-2019?source=tweet\" data-url=\"https://seekingalpha.com/news/3423632-iamgoldminus-10-sees-lower-production-higher-costs-in-2019\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423613\" data-ts=\"1547670066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423613-options-seen-for-pg-and-e-shares-keep-sliding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Few options seen for PG&amp;E, so shares keep sliding</a></h4><ul><li>Analysts say the continued slide in PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='red'>-2.2%</font>) shares reflects growing concerns among investors that California's governor and lawmakers <a href=\"https://www.wsj.com/articles/pg-e-shares-keep-tumbling-as-california-rescue-chances-dim-11547663679\" target=\"_blank\">will not offer the company an alternative to bankruptcy</a> in the near term, as rising public opposition to PG&amp;E complicates the potential for a state rescue.</li><li>\u201cInvestors are starting to realize this is going to be quite a protracted process to figure out a solution that works for all constituents,\u201d says Morgan Stanley analyst Stephen Byrd.</li><li>PG&amp;E\u2019s intent to file for bankruptcy protection and subsequent statements from California officials imply \u201cthat a rescue mission by elected leaders may not be forthcoming, forecasting a potentially contentious bankruptcy proceeding,\u201d says Rob Rains of Washington Analysis LLC.</li><li>Wells Fargo's Neil Kalton <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/19/01/12993801/analysts-talk-utility-stocks-in-the-aftermath-of-pg-e-b\" target=\"_blank\">downgrades</a> PG&amp;E to Market Perform from Outperform and cuts his price target to $10 from $15, predicting a \u201chighly complex and lengthy\u201d bankruptcy process.</li><li>A takeover by the state or local governments is among <a href=\"https://finance.yahoo.com/news/future-bankrupt-pg-e-may-100002847.html\" target=\"_blank\">many possible outcomes</a> for PG&amp;E; possibilities also include selling off its gas business as well as its San Francisco headquarters - with so little commercial real estate space, PG&amp;E's 1.7M sq. ft. HQ could be <a href=\"https://finance.yahoo.com/news/pg-e-apos-san-francisco-141724460.html\" target=\"_blank\">valued at more than $1B</a>.</li><li>But Morningstar analyst Travis Miller <a href=\"https://www.bloomberg.com/news/articles/2019-01-16/lone-pg-e-bull-refuses-to-ditch-buy-rating-after-80-wipeout\" target=\"_blank\">reiterates his bullish view</a> of the stock, saying PG&amp;E shareholders will likely \u201cretain post-bankruptcy equity value\u201d that\u2019s greater than the market is pricing in, adding that \u201cif regulatory and legal outcomes happen as we think they will, buyers could see a substantial return on their investment today.\u201d</li></ul><div class=\"tiny-share-widget\" data-id=\"3423613\" data-linked=\"Few options seen for PG&amp;E, so shares keep sliding\" data-tweet=\"$PCG - Few options seen for PG&amp;E, so shares keep sliding https://seekingalpha.com/news/3423613-options-seen-for-pg-and-e-shares-keep-sliding?source=tweet\" data-url=\"https://seekingalpha.com/news/3423613-options-seen-for-pg-and-e-shares-keep-sliding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423606\" data-ts=\"1547669558\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423606-red-hat-drops-mongodb-over-sspl-mdbminus-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat drops MongoDB over SSPL; MDB -3%</a></h4><ul><li>Red Hat (<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a> <font color='red'>-0.1%</font>) is <a href=\"https://www.zdnet.com/article/mongodb-open-source-server-side-public-license-rejected/#ftag=RSSbaffb68\" target=\"_blank\">removing</a> MongoDB (NASDAQ:<a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a>) from its Enterprise Linux and Fedora, the Linux distribution the company sponsors, due to MDB's new Server Side Public License.</li><li><ul><li>Red Hat's Technical and Community Outreach Program Manager Tom Callaway: \"It is the belief of Fedora that the SSPL is intentionally crafted to be aggressively discriminatory towards a specific class of users.\"</li></ul></li><li><ul><li>SSPL tells companies offering MongoDB services they must open-source all programs used to make the software available as a service. The point is to force companies to go open-source or choose one of MongoDB's commercial products.</li></ul></li><li><ul><li>Amazon responded by <a href=\"https://seekingalpha.com/news/3422037-amazon-comes-mongodb-mdb-minus-15-percent\" target=\"_blank\">launching DocumentDB</a>, a managed database that's compatible with existing MongoDB applications and tools. DocumentDB works with MongoDB version 3.6, which predates the SSPL license.</li></ul></li><li><ul><li>MDB shares are <font color=\"red\">down 3.2%</font> to $75.93.</li></ul></li></ul><div class=\"tiny-share-widget\" data-id=\"3423606\" data-linked=\"Red Hat drops MongoDB over SSPL; MDB -3%\" data-tweet=\"$RHT $RHT $MDB - Red Hat drops MongoDB over SSPL; MDB -3% https://seekingalpha.com/news/3423606-red-hat-drops-mongodb-over-sspl-mdbminus-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3423606-red-hat-drops-mongodb-over-sspl-mdbminus-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423602\" data-ts=\"1547668834\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AWSM\" target=\"_blank\">AWSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423602-awsm-clps-efii-and-vhc-tops-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AWSM, CLPS, EFII and VHC tops tech movers</a></h4><ul><li><strong>Gainers: </strong>Cool Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a>) <font color=\"green\">+23%</font>. CLPS Incorporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CLPS' title='CLPS, Inc'>CLPS</a>) <font color=\"green\">+20%</font>. Maxwell Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/MXWL' title='Maxwell Technologies, Inc.'>MXWL</a>) <font color=\"green\">+16%</font>. Cardlytics (NASDAQ:<a href='https://seekingalpha.com/symbol/CDLX' title='Cardlytics, Inc.'>CDLX</a>) <font color=\"green\">+12%</font>. CPS Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a>) <font color=\"green\">+10%</font>.</li> <li><strong>Losers: </strong>Electronics for Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a>) <font color=\"red\">-19%</font>. VirnetX Holding (NYSEMKT:<a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a>) <font color=\"red\">-18%</font>. Internet Gold - Golden Lines (NASDAQ:<a href='https://seekingalpha.com/symbol/IGLD' title='Internet Gold Golden Lines Ltd.'>IGLD</a>) <font color=\"red\">-17%</font>. Sonic Foundry (<a href='https://seekingalpha.com/symbol/SOFO' title='Sonic Foundry, Inc.'>OTC:SOFO</a>) <font color=\"red\">-17%</font>. Qutoutiao (NASDAQ:<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao'>QTT</a>) <font color=\"red\">-15%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423602\" data-linked=\"AWSM, CLPS, EFII and VHC tops tech movers\" data-tweet=\"$AWSM $AWSM $CLPS - AWSM, CLPS, EFII and VHC tops tech movers https://seekingalpha.com/news/3423602-awsm-clps-efii-and-vhc-tops-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3423602-awsm-clps-efii-and-vhc-tops-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423590\" data-ts=\"1547666421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AA\" target=\"_blank\">AA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423590-alcoa-slips-senate-lacks-votes-to-block-sanctions-removal-for-rusal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alcoa slips as Senate lacks votes to block sanctions removal for Rusal</a></h4><ul><li>Alcoa (<a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color=\"red\">-1.4%</font>) tumbles into the red after the U.S. Senate <a href=\"https://www.rollcall.com/news/congress/chuck-schumers-campaign-block-russia-sanctions-relief-comes-short\" target=\"_blank\">falls short of the votes needed</a> to block The Trump administration's efforts to remove sanctions from Russian aluminum company Rusal.</li><li>Shortly after securing 57 votes to support a motion to proceed to the joint resolution disapproving  of the Treasury department's move to lift sanctions on three Russian firms that have  been controlled by sanctioned oligarch Oleg Deripaska, the same number  of senators voted to limit debate - three short of the 60  needed to cut off debate and get the measure to a final passage vote.</li><li>The Treasury Department said last month that it would lift sanctions imposed in April on the core businesses of Deripaska, including Rusal, the world\u2019s largest aluminum producer outside China.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423590\" data-linked=\"Alcoa slips as Senate lacks votes to block sanctions removal for Rusal\" data-tweet=\"$AA - Alcoa slips as Senate lacks votes to block sanctions removal for Rusal https://seekingalpha.com/news/3423590-alcoa-slips-senate-lacks-votes-to-block-sanctions-removal-for-rusal?source=tweet\" data-url=\"https://seekingalpha.com/news/3423590-alcoa-slips-senate-lacks-votes-to-block-sanctions-removal-for-rusal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423585\" data-ts=\"1547665205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSN\" target=\"_blank\">OSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423585-ossen-innovation-and-arcadia-biosciences-among-energy-materials-gainers-legacy-reserves-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ossen Innovation and Arcadia Biosciences among Energy/Materials gainers; Legacy Reserves and PEDEVCO among losers</a></h4><ul><li><b>Gainers: </b>Ossen Innovation (NASDAQ:<a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a>) <font color=\"green\">+8%</font>. Arcadia Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a>) <font color=\"green\">+6%</font>. Talos Energy (NYSE:<a href='https://seekingalpha.com/symbol/TALO' title='Talos Energy Inc'>TALO</a>) <font color=\"green\">+6%</font>. Eclipse Resources (NYSE:<a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a>) <font color=\"green\">+6%</font>. VOC Energy Trust (NYSE:<a href='https://seekingalpha.com/symbol/VOC' title='VOC Energy Trust'>VOC</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Legacy Reserves (NASDAQ:<a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a>) <font color=\"red\">-19%</font>. PEDEVCO (NYSEMKT:<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a>) <font color=\"red\">-12%</font>. Aceto (NASDAQ:<a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a>) <font color=\"red\">-11%</font>. IAMGOLD (NYSE:<a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a>) <font color=\"red\">-10%</font>. Rosehill Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423585\" data-linked=\"Ossen Innovation and Arcadia Biosciences among Energy/Materials gainers; Legacy Reserves and PEDEVCO among losers\" data-tweet=\"$OSN $OSN $RKDA - Ossen Innovation and Arcadia Biosciences among Energy/Materials gainers; Legacy Reserves and PEDEVCO among losers https://seekingalpha.com/news/3423585-ossen-innovation-and-arcadia-biosciences-among-energy-materials-gainers-legacy-reserves-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3423585-ossen-innovation-and-arcadia-biosciences-among-energy-materials-gainers-legacy-reserves-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423573\" data-ts=\"1547664822\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGND\" target=\"_blank\">LGND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423573-ligand-pharma-down-22-on-bearish-citron-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ligand Pharma down 22% on bearish Citron report</a></h4><ul><li>Ligand Pharmaceuticals (<a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a> <font color=\"red\">-21.9%</font>) is down on more than a 5x surge in volume on the heels of a <a href=\"https://citronresearch.com/wp-content/uploads/2019/01/The-Smoking-Gun-on-Ligand-Pharmaceuticals.pdf\" target=\"_blank\">report </a>from Citron Research supporting a $35 (66% downside risk) price target. Key points:</li><li>Royalty income expected to decline from 2023 - 20-26 before ramping back up, driven by its pipeline.</li><li>Fair (pre-pipeline) value is $20 per share based on current royalties, net operating losses and cash.</li><li>The dominance of \"The Big 6\" is a myth since Viking Therapeutics (<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics'>VKTX</a> <font color=\"red\">-3.9%</font>) will account for more than half of its milestones while Eli Lilly and Bristol-Myers Squibb account for less than 7%. Citron says that if this was \"even remotely realistic,\" then LGND would buy the company outright instead of repurchasing its own stock and selling some of the VKTX shares it owns.</li><li>Citron also questions the realism of $364M in expected milestones from Vernalis, which it says LGND bought for $11M (it <a href=\"https://seekingalpha.com/news/3380993-ligand-pharma-bid-43m-british-drug-developer-vernalis\" target=\"_blank\">bid the equivalent</a> of $43M in August 2018), considering one of the two key product candidates failed a mid-stage study and the other is associated with serious side effects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423573\" data-linked=\"Ligand Pharma down 22% on bearish Citron report\" data-tweet=\"$LGND $LGND $VKTX - Ligand Pharma down 22% on bearish Citron report https://seekingalpha.com/news/3423573-ligand-pharma-down-22-on-bearish-citron-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3423573-ligand-pharma-down-22-on-bearish-citron-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423575\" data-ts=\"1547663754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNFI\" target=\"_blank\">UNFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423575-united-natural-foodsplus-3-after-guidance-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Natural Foods +3% after guidance update</a></h4><ul><li>United Natural Foods (<a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a> <font color=\"green\">+2.8%</font>) rallies after a short trading halt in front of the release of investor day presentation slides.</li><li>The company reaffirmed 2019 guidance for revenue of $21.5B to $22.0B and EPS of $1.69 to $1.89 vs. $1.65 consensus.</li><li>Investors may also have their eyes on the long-term outlook from UNFI for FY22 FY22 revenue of $27.0B to $27.5B and adjusted EBITDA of $875M to $925M.</li><li><a href=\"https://seekingalpha.com/filing/4304781\" target=\"_blank\">SEC Form 8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3423575\" data-linked=\"United Natural Foods +3% after guidance update\" data-tweet=\"$UNFI - United Natural Foods +3% after guidance update https://seekingalpha.com/news/3423575-united-natural-foodsplus-3-after-guidance-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3423575-united-natural-foodsplus-3-after-guidance-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423574\" data-ts=\"1547663750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LASR\" target=\"_blank\">LASR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423574-stifel-sees-growth-for-nlight-lasrplus-6_6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel sees growth for nLIGHT; LASR +6.6%</a></h4><ul><li>Stifel says nLIGHT (NASDAQ:<a href='https://seekingalpha.com/symbol/LASR' title='nLIGHT, Inc.'>LASR</a>) can grow this year even with a potential decline in the fiber laser market.</li><li>Analyst Patrick Ho cites share gains and continuing new product traction and sees limited downside at the current price.</li><li>Rating reiterated at Buy with a $32 target.</li><li>Source: Bloomberg First Word.</li><li>LASR is <font color=\"green\">up 6.6%</font> to $19.05.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423574\" data-linked=\"Stifel sees growth for nLIGHT; LASR +6.6%\" data-tweet=\"$LASR - Stifel sees growth for nLIGHT; LASR +6.6% https://seekingalpha.com/news/3423574-stifel-sees-growth-for-nlight-lasrplus-6_6?source=tweet\" data-url=\"https://seekingalpha.com/news/3423574-stifel-sees-growth-for-nlight-lasrplus-6_6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423567\" data-ts=\"1547662608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423567-bank-stocks-rally-wiping-out-of-decembers-slump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank stocks rally, wiping out most of December&#39;s slump</a></h4><ul><li>Bank stocks rally after Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='green'>+8.2%</font>) and Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='green'>+7.3%</font>) turn in better-than-expected earnings and wiping out most of their December decline.</li><li>Financial Select Sector SPDR ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>)<font color=\"green\"> rises 2.5% </font>in early afternoon trading and touches its highest point in more than a month. The last time it reached $25.51 was Dec. 7.</li><li>The SPDR S&amp;P Bank ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>), mostly regional banks, advances <font color=\"green\">2.4%</font>.</li><li>All the big banks gain: Morgan Stanley (NYSE:<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>), which reports Q4 results Thursday, rises 4.6%; Wells Fargo (<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a> <font color='green'>+3.2%</font>), JPMorgan Chase (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color='green'>+1.5%</font>), Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='green'>+1.7%</font>).</li><li>Among regional banks, Comerica (<a href='https://seekingalpha.com/symbol/CMA' title='Comerica Inc.'>CMA</a> <font color='green'>+4.8%</font>) jumps on an earnings beat; with Bank OZK (<a href='https://seekingalpha.com/symbol/OZK' title='Bank OZK'>OZK</a> <font color='green'>+3.4%</font>), Huntington Bancshares (<a href='https://seekingalpha.com/symbol/HBAN' title='Huntington Bancshares Incorporated'>HBAN</a> <font color='green'>+2.8%</font>), and KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='green'>+2.9%</font>) advancing strongly.</li><li>PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a> <font color='green'>+0.2%</font>) slips on weaker-than-expected Q4 results.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, RWW-OLD, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3423567\" data-linked=\"Bank stocks rally, wiping out most of December&#39;s slump\" data-tweet=\"$GS $GS $BAC - Bank stocks rally, wiping out most of December&#39;s slump https://seekingalpha.com/news/3423567-bank-stocks-rally-wiping-out-of-decembers-slump?source=tweet\" data-url=\"https://seekingalpha.com/news/3423567-bank-stocks-rally-wiping-out-of-decembers-slump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423566\" data-ts=\"1547662531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALRN\" target=\"_blank\">ALRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423566-aileron-up-35-on-advancement-of-alrnminus-6924-ibrance-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aileron up 35% on advancement of ALRN-6924 + Ibrance study</a></h4><ul><li>Thinly traded nano cap Aileron Therapeutics (<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a> <font color=\"green\">+35.1%</font>) is up on an 8x surge in volume following its <a href=\"https://seekingalpha.com/pr/17382722-aileron-therapeutics-commences-enrollment-phase-2a-expansion-cohort-alrnminus-6924\" target=\"_blank\">announcement </a>that dosing is underway in an expansion cohort in its Phase 2a clinical trial evaluating lead candidate ALRN-6924, combined with Pfizer's (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"red\">-0.6%</font>) IBRANCE (palbociclib), in patients with MDM2-amplified solid tumors.</li><li>The new arm will enroll up to 25 participants. Preliminary data should be available in H2.</li><li>ALRN-6924 is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt its interaction with <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161369/\" target=\"_blank\">MDMX and MDM2</a>, two proteins that interfere with its action.</li><li>Palbociclib inhibits two enzymes, CDK4 and CDK6, that play key roles in the cell cycle. Blocking their action interferes with cancer cell proliferation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423566\" data-linked=\"Aileron up 35% on advancement of ALRN-6924 + Ibrance study\" data-tweet=\"$ALRN $ALRN $PFE - Aileron up 35% on advancement of ALRN-6924 + Ibrance study https://seekingalpha.com/news/3423566-aileron-up-35-on-advancement-of-alrnminus-6924-ibrance-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3423566-aileron-up-35-on-advancement-of-alrnminus-6924-ibrance-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423563\" data-ts=\"1547661530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QFIN\" target=\"_blank\">QFIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423563-360-finance-leads-financial-gainers-hexindai-only-loser\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">360 Finance leads financial gainers; Hexindai the only loser</a></h4><ul><li><b>Gainers:</b> 360 Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/QFIN' title='360 Finance'>QFIN</a>) <font color=\"green\">+10%</font>. Spirit MTA REIT (NYSE:<a href='https://seekingalpha.com/symbol/SMTA' title='Spirit MTA REIT'>SMTA</a>) <font color=\"green\">+10%</font>. The Goldman Sachs Group (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>) <font color=\"green\">+8%</font>. Deutsche Bank Aktiengesellschaft (NYSE:<a href='https://seekingalpha.com/symbol/DB' title='Deutsche Bank AG'>DB</a>) <font color=\"green\">+8%</font>. Bank of America (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers:</b> Hexindai (NASDAQ:<a href='https://seekingalpha.com/symbol/HX' title='Hexindai Inc.'>HX</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423563\" data-linked=\"360 Finance leads financial gainers; Hexindai the only loser\" data-tweet=\"$QFIN $QFIN $SMTA - 360 Finance leads financial gainers; Hexindai the only loser https://seekingalpha.com/news/3423563-360-finance-leads-financial-gainers-hexindai-only-loser?source=tweet\" data-url=\"https://seekingalpha.com/news/3423563-360-finance-leads-financial-gainers-hexindai-only-loser\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423561\" data-ts=\"1547660894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TBLT\" target=\"_blank\">TBLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423561-snap-nm-lgcy-and-fdc-among-notable-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SNAP, NM, LGCY and FDC among notable midday movers</a></h4><ul><li><strong>Gainers: </strong>ToughBuilt Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/TBLT' title='ToughBuilt Industries, Inc.'>TBLT</a>) <font color=\"green\">+187%</font>. Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) <font color=\"green\">+93%</font>. Hancock Jaffe Laboratories (NASDAQ:<a href='https://seekingalpha.com/symbol/HJLI' title='Hancock Jaffe Laboratories'>HJLI</a>) <font color=\"green\">+34%</font>. Reebonz Holding (<a href='https://seekingalpha.com/symbol/RBZ' title='Reebonz Holding Ltd. Class A'>RBZ</a>) <font color=\"green\">+23%</font>. Vaccinex (NASDAQ:<a href='https://seekingalpha.com/symbol/VCNX' title='Vaccinex'>VCNX</a>) <font color=\"green\">+21%</font>. First Data (NYSE:<a href='https://seekingalpha.com/symbol/FDC' title='First Data Corporation'>FDC</a>) <font color=\"green\">+21%</font>. Altimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) <font color=\"green\">+20%</font>. CLPS Incorporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CLPS' title='CLPS, Inc'>CLPS</a>) <font color=\"green\">+19%</font>. Mercer International (NASDAQ:<a href='https://seekingalpha.com/symbol/MERC' title='Mercer International Inc.'>MERC</a>) <font color=\"green\">+19%</font>. Integrated Media Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/IMTE' title='Integrated Media Technology Limited'>IMTE</a>) <font color=\"green\">+16%</font>.</li> <li><strong>Losers: </strong>Aptinyx (NASDAQ:<a href='https://seekingalpha.com/symbol/APTX' title='Aptinyx'>APTX</a>) <font color=\"red\">-73%</font>. Legacy Reserves (NASDAQ:<a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a>) <font color=\"red\">-19%</font>. China Ceramics (NASDAQ:<a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a>) <font color=\"red\">-19%</font>. Electronics for Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a>) <font color=\"red\">-18%</font>. Internet Gold - Golden Lines (NASDAQ:<a href='https://seekingalpha.com/symbol/IGLD' title='Internet Gold Golden Lines Ltd.'>IGLD</a>) <font color=\"red\">-17%</font>. PEDEVCO (NYSEMKT:<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a>) <font color=\"red\">-13%</font>. NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/NFEC' title='NF Energy Saving Corp.'>NFEC</a>) <font color=\"red\">-11%</font>. Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) <font color=\"red\">-12%</font>. Navios Maritime Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NM' title='Navios Maritime Holdings Inc.'>NM</a>) <font color=\"red\">-12%</font>. Kitov Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a>) <font color=\"red\">-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423561\" data-linked=\"SNAP, NM, LGCY and FDC among notable midday movers\" data-tweet=\"$TBLT $TBLT $BIOC - SNAP, NM, LGCY and FDC among notable midday movers https://seekingalpha.com/news/3423561-snap-nm-lgcy-and-fdc-among-notable-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3423561-snap-nm-lgcy-and-fdc-among-notable-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423552\" data-ts=\"1547659250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHHBY\" target=\"_blank\">RHHBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423552-hospitals-squeezed-high-drug-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hospitals squeezed by high drug costs</a></h4><ul><li>A <a href=\"https://www.healthcaredive.com/news/hospital-drug-spend-spiked-19-from-2015-17-coalition-says/546128/?utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Issue:%202019-01-16%20Healthcare%20Dive%20%5Bissue:18955%5D&amp;utm_term=Healthcare%20Dive\" target=\"_blank\">study </a>funded by the American Hospital Association, Federation of American Hospitals and the American Society of Health-System Pharmacists found that total drug spend per hospital admission rose 18.5% between 2015 and 2017, adding $1.8M in additional costs for an average hospital.</li><li>Outpatient drug spending per admission rose almost 30% while inpatient spending for medicines rose 10%. Price hikes as high as 80% or more occurred in anesthetics, parenteral solutions, opioid agonists and chemo.</li><li>More than 90% of hospitals surveyed had to identify alternative therapies to mitigate the impact of price increases and drug shortages. One in four had to downsize staff.</li><li>The price of Roche's stroke med Activase increased 19% to $4,143. Johnson &amp; Johnson's Remicade, AbbVie's Humira and Amgen's Enbrel increased between 15 - 21%.</li><li>The majority of hospitals reported that competition had little effect on prices. Two of the 10 most expensive drugs in fiscal 2017 had generic or biosimilar alternatives enter the market in 2016, but the two still increased 4.1%, albeit more modestly than the 14.4% average hike among the other eight.</li><li>About 750 hospitals have joined a non-profit venture called Civica Rx aimed at managing drug costs and supply.</li><li><p><a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a>, <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a>, <a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a>, <a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a>, <a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a>, <a href='https://seekingalpha.com/symbol/PPH' title='VanEck Vectors Pharmaceutical ETF'>PPH</a>, <a href='https://seekingalpha.com/symbol/VHT' title='Vanguard Health Care ETF'>VHT</a>, <a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>, <a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>, <a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>, <a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>, <a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>, <a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>, <a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>, <a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>, <a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>, <a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a>, <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>, <a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>, <a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>, <a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>, <a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>, <a href='https://seekingalpha.com/symbol/TAK' title='Takeda Pharmaceutical Co., Ltd. ADR'>TAK</a>, <a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a>, <a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>, <a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a>, <a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a>, <a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>, <a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>, <a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a></p><div> </div></li></ul><div class=\"tiny-share-widget\" data-id=\"3423552\" data-linked=\"Hospitals squeezed by high drug costs\" data-tweet=\"$RHHBY $XLV $IBB - Hospitals squeezed by high drug costs https://seekingalpha.com/news/3423552-hospitals-squeezed-high-drug-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3423552-hospitals-squeezed-high-drug-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>196&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423551\" data-ts=\"1547659133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MXWL\" target=\"_blank\">MXWL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423551-maxwell-techplus-13-after-cfo-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxwell Tech +13% after CFO presentation</a></h4><ul><li>Maxwell Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/MXWL' title='Maxwell Technologies, Inc.'>MXWL</a>) <font color=\"green\">jumps 13%</font> after CFO David Lyle's presentation at the Annual Needham Growth Conference.</li><li>In auto, Lyle says MXWL has \"multiple large scale design wins on the horizon\", and he sees strong demand for a peak power application targeted at hybrid electric vehicles with $1B in revenue opportunities.</li><li>Other potential catalysts:  Battery retrofit subsystem for ultracapacitors that could provide some growth in 2H19 and significant opportunities for lithium capacitors, particularly in the China market.</li><li>Source: Bloomberg First Word.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423551\" data-linked=\"Maxwell Tech +13% after CFO presentation\" data-tweet=\"$MXWL - Maxwell Tech +13% after CFO presentation https://seekingalpha.com/news/3423551-maxwell-techplus-13-after-cfo-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3423551-maxwell-techplus-13-after-cfo-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423548\" data-ts=\"1547658146\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MERC\" target=\"_blank\">MERC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423548-mercer-international-leads-consumer-gainers-kandi-technologies-and-energous-in-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mercer International leads consumer gainers; Kandi Technologies and Energous in losers</a></h4><ul><li><b>Gainers: </b>Mercer International (NASDAQ:<a href='https://seekingalpha.com/symbol/MERC' title='Mercer International Inc.'>MERC</a>) <font color=\"green\">+19%</font>. Unique Fabricating (NYSEMKT:<a href='https://seekingalpha.com/symbol/UFAB' title='Unique Fabricating, Inc.'>UFAB</a>) <font color=\"green\">+12%</font>. CTI Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/CTIB' title='CTI Industries Corporation'>CTIB</a>) <font color=\"green\">+8%</font>. Dogness (NASDAQ:<a href='https://seekingalpha.com/symbol/DOGZ' title='Dogness &#40;International&#41; Corporation Class A'>DOGZ</a>) <font color=\"green\">+8%</font>. S&amp;W Seed (NASDAQ:<a href='https://seekingalpha.com/symbol/SANW' title='S&W Seed Co'>SANW</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) <font color=\"red\">-6%</font>. Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423548\" data-linked=\"Mercer International leads consumer gainers; Kandi Technologies and Energous in losers\" data-tweet=\"$MERC $MERC $UFAB - Mercer International leads consumer gainers; Kandi Technologies and Energous in losers https://seekingalpha.com/news/3423548-mercer-international-leads-consumer-gainers-kandi-technologies-and-energous-in-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3423548-mercer-international-leads-consumer-gainers-kandi-technologies-and-energous-in-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423545\" data-ts=\"1547657256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423545-snapminus-10_9-in-fallout-from-cfos-quick-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap -10.9% in fallout from CFO&#39;s quick exit</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) is <font color=\"red\">down 10.9%</font> after its latest <a href=\"https://seekingalpha.com/news/3423321-snap-minus-4_9-percent-cfo-resigns\" target=\"_blank\">executive departure</a>, the exit of Chief Financial Officer Tim Stone after just eight months on the job.</li>    <li>He leaves behind much of his $20M sign-on bonus, and \u201cfor a talented CFO to leave after only eight months suggests he or she was <a href=\"https://www.wsj.com/articles/snap-finance-chief-joins-executive-exodus-11547599190?mod=hp_major_pos16\" target=\"_blank\">surprised with what they found</a>,\u201d says Peter Crist of executive search firm Crist|Kolder.</li>    <li>The departure also follows this week's departure of Jason Halbert, head of human resources.</li>    <li>RBC's Mark Mahaney has downgraded to Sector Perform from Outperform, with an eye more to Stone's exit than the guidance hints the company's giving. Valuation's not compelling, he suggests, and now it's about whether management can execute a turnaround, though he maintains an $8 price target (now implying 37% upside).</li>    <li>Pivotal's Brian Wieser (Hold, $6 target) thinks reports that Evan Spiegel has been increasingly centralizing control could be driving the heavy turnover in the exec ranks, though a <font color=\"red\">50% drop</font> in share price over six months could affect employee thinking about the future as well.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423545\" data-linked=\"Snap -10.9% in fallout from CFO&#39;s quick exit\" data-tweet=\"$SNAP - Snap -10.9% in fallout from CFO&#39;s quick exit https://seekingalpha.com/news/3423545-snapminus-10_9-in-fallout-from-cfos-quick-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3423545-snapminus-10_9-in-fallout-from-cfos-quick-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423541\" data-ts=\"1547657067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRGDF\" target=\"_blank\">DRGDF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423541-detour-gold-announces-record-production-for-q4-fy-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Detour Gold announces record production for Q4, FY 2018</a></h4><ul><li>Detour Gold (<a href='https://seekingalpha.com/symbol/DRGDF' title='Detour Gold Corp.'>OTCPK:DRGDF</a> <font color='green'>+3.3%</font>) reports its <a href=\"https://seekingalpha.com/pr/17381484-detour-gold-announces-record-production-q4-full-year-2018\" target=\"_blank\">best ever quarterly production</a> of 158.2K oz. of gold from its Detour Lake mine in Ontario and 621.1K oz. for the full year, up 9% Y/Y and above the mid-point of the company's 595K-635K oz. annual guidance.</li><li>Detour says Q4 represented its third successive quarter with overall operational improvement with record total tonnage mined and gold production.</li><li>Detour also says it expects FY 2018 capex to come in below guidance of $265M-$285M due to delays in the construction of Cell 2 of the tailing facility, deferral of other discretionary capital and a weaker Canadian dollar than budgeted.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423541\" data-linked=\"Detour Gold announces record production for Q4, FY 2018\" data-tweet=\"$DRGDF - Detour Gold announces record production for Q4, FY 2018 https://seekingalpha.com/news/3423541-detour-gold-announces-record-production-for-q4-fy-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3423541-detour-gold-announces-record-production-for-q4-fy-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423538\" data-ts=\"1547656409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EA\" target=\"_blank\">EA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423538-eaminus-1_8-amid-reports-ambitious-star-wars-game-is-canceled\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EA -1.8% amid reports ambitious &#39;Star Wars&#39; game is canceled</a></h4><ul>   <li>Electronic Arts (NASDAQ:<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a>) is <font color=\"red\">off 1.8%</font> after a Kotaku report that an open-world game based on <i>Star Wars</i> has been <a href=\"https://kotaku.com/ea-cancels-open-world-star-wars-game-1831786371\" target=\"_blank\">canceled</a>.</li>    <li>The game, in development in Vancouver, was still in early stages but had been announced in 2017.</li>    <li>EA is now focused on a smaller-scale <i>Star Wars</i> project expected to come out in late 2020, sooner than the canceled game would have, according to the report.</li>    <li>Morgan Stanley's Brian Nowak says that's hurting the multiple that investors are willing to pay, following a \"recent string of misexecution\" out of the company. If EA can deliver a strong <i>Jedi: Fallen Order</i> in 2020 along with two other hits, this might be a speed bump; but otherwise EA might not be able to retain Disney's contract at its 2024 expiration. (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423538\" data-linked=\"EA -1.8% amid reports ambitious &#39;Star Wars&#39; game is canceled\" data-tweet=\"$EA - EA -1.8% amid reports ambitious &#39;Star Wars&#39; game is canceled https://seekingalpha.com/news/3423538-eaminus-1_8-amid-reports-ambitious-star-wars-game-is-canceled?source=tweet\" data-url=\"https://seekingalpha.com/news/3423538-eaminus-1_8-amid-reports-ambitious-star-wars-game-is-canceled\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423533\" data-ts=\"1547655977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423533-biopharma-firms-under-pressure-on-brexit-uncertainty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biopharma firms under pressure on Brexit uncertainty</a></h4><ul><li>Some members of Big Biopharma are under modest pressure in apparent reaction to the <a href=\"https://www.independent.co.uk/news/business/news/brexit-no-deal-medicine-supply-germany-health-trade-pharma-industry-a8730531.html\" target=\"_blank\">uncertainty </a>with drug supplies and potential regulatory disruptions associated with a no-deal Brexit. A messy divorce between the UK and European Union could create problems with supply chains since UK-registered products may need additional certifications to be sold on the continent.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a> <font color=\"green\">+1.2%</font>)(<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color=\"red\">-0.2%</font>)(<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color=\"green\">+0.1%</font>)(<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"green\">+0.5%</font>)(<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color=\"red\">-1%</font>)(<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"red\">-0.6%</font>)(<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color=\"red\">-1.4%</font>)(<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color=\"red\">-0.8%</font>)(<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color=\"red\">-0.2%</font>)(<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color=\"green\">+0.8%</font>)(<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color=\"red\">-0.2%</font>)(<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"red\">-0.7%</font>)(<a href='https://seekingalpha.com/symbol/TAK' title='Takeda Pharmaceutical Co., Ltd. ADR'>TAK</a> <font color=\"red\">-2.7%</font>)(<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"green\">+0.2%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"red\">-0.1%</font>)(<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color=\"red\">-0.3%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"red\">-0.8%</font>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color=\"red\">-0.4%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3423533\" data-linked=\"Biopharma firms under pressure on Brexit uncertainty\" data-tweet=\"$BHC $BHC $RHHBY - Biopharma firms under pressure on Brexit uncertainty https://seekingalpha.com/news/3423533-biopharma-firms-under-pressure-on-brexit-uncertainty?source=tweet\" data-url=\"https://seekingalpha.com/news/3423533-biopharma-firms-under-pressure-on-brexit-uncertainty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423532\" data-ts=\"1547655753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423532-sears-survives-what-now\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears survives, what now?</a></h4><ul> <li>Investors dabbling with the OTC-listed shares of Sears Holdings (<a href='https://seekingalpha.com/symbol/SHLDQ' title='Sears Holdings Corporation'>OTCPK:SHLDQ</a>) are seeing a <font color=\"green\">35% gain</font> today off news that Eddie Lampert may in fact keep the department store chain alive in some form.</li> <li>Some Sears creditors are expected to challenge the deal in front of the bankruptcy judge before Lampert can claim victory.</li> <li>Even if Sears survives, <a href=\"https://www.usatoday.com/story/money/2019/01/16/sears-bankruptcy-auction-eddie-lampert/2590973002/\" target=\"_blank\">skepticism</a> persists within the retail industry. \"While there is no doubt that a shrunken Sears will be more viable than the larger entity which struggled to turn a profit, we remain extremely pessimistic about the chain's future,\" writes GlobalData Retail managing director Neil Saunders.</li><li>Meanwhile, Bloomberg <a href=\"https://www.bloomberg.com/opinion/articles/2019-01-16/sears-three-things-eddie-lampert-can-do-to-give-it-a-chance\" target=\"_blank\">suggests</a> that Lampert and team give up on the Kmart chain and its decimating margins.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3423347-lampert-prevails-sears-bankruptcy-auction\" target=\"_blank\">Lampert prevails in Sears bankruptcy auction</a> (Jan. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423532\" data-linked=\"Sears survives, what now?\" data-tweet=\"$SHLDQ - Sears survives, what now? https://seekingalpha.com/news/3423532-sears-survives-what-now?source=tweet\" data-url=\"https://seekingalpha.com/news/3423532-sears-survives-what-now\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>146&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423531\" data-ts=\"1547655363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YELP\" target=\"_blank\">YELP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423531-yelpplus-2-sqn-calls-for-new-directors-strategic-evaluation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yelp +2% as SQN calls for new directors, strategic evaluation</a></h4><ul>   <li>Yelp (NYSE:<a href='https://seekingalpha.com/symbol/YELP' title='Yelp'>YELP</a>) is <font color=\"green\">up 2%</font> after shareholder SQN issues a new call for the company to add new directors and look at strategic alternatives.</li>    <li>In a <a href=\"https://seekingalpha.com/filing/4304544\" target=\"_blank\">filing</a>, SQN founder Amish Mehta notes SQN is a long-term investor in its fourth year holding the company, but \"after years of Yelp underperformance, we have lost patience and believe the Board needs fresh perspectives and stockholder representation.\"</li>    <li>SQN is not an activist holder, Mehta says, but it's prepared to take recommendations straight to stockholders for support. SQN is beneficial owner of more than 4% of Yelp stock.</li>    <li>Yelp has \"dramatically underperformed with no meaningful accountability,\" SQN says, and stockholders need to seize the opportunity to replace three of eight directors this year.</li>    <li>And \"a refreshed board should immediately evaluate strategic alternatives including a possible sale of Yelp.\" Implementing its recommendations could result in a stock price of $55-$65 (59-89% appreciation from the Dec. 7 closing), SQN says. Alternately an immediate sale to private equity could yield a price of $47-$50/share, or higher with strategic bidders. Yelp's at $35.66 currently.</li>    <li>Yelp says it's <a href=\"https://seekingalpha.com/pr/17382605-yelp-responds-press-release-sqn-investors\" target=\"_blank\">willing and open to meeting with SQN</a> to hear more from them on the topics.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423531\" data-linked=\"Yelp +2% as SQN calls for new directors, strategic evaluation\" data-tweet=\"$YELP - Yelp +2% as SQN calls for new directors, strategic evaluation https://seekingalpha.com/news/3423531-yelpplus-2-sqn-calls-for-new-directors-strategic-evaluation?source=tweet\" data-url=\"https://seekingalpha.com/news/3423531-yelpplus-2-sqn-calls-for-new-directors-strategic-evaluation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423527\" data-ts=\"1547654554\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423527-biocept-leads-healthcare-gainers-achieve-life-sciences-and-revance-therapeutics-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept leads healthcare gainers; Achieve Life Sciences and Revance Therapeutics among losers</a></h4><ul><li><b>Gainers: </b>Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) <font color=\"green\">+45%</font>. PetIQ (NASDAQ:<a href='https://seekingalpha.com/symbol/PETQ' title='PetIQ'>PETQ</a>) <font color=\"green\">+12%</font>. Invacare (NYSE:<a href='https://seekingalpha.com/symbol/IVC' title='Invacare Corporation'>IVC</a>) <font color=\"green\">+11%</font>. Altimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) <font color=\"green\">+11%</font>. Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a>) <font color=\"green\">+10%</font>.</li><li><b>Losers: </b>Aptinyx (NASDAQ:<a href='https://seekingalpha.com/symbol/APTX' title='Aptinyx'>APTX</a>) <font color=\"red\">-71%</font>. Kitov Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a>) <font color=\"red\">-23%</font>. Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"red\">-9%</font>. Revance Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a>) <font color=\"red\">-8%</font>. Onconova Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423527\" data-linked=\"Biocept leads healthcare gainers; Achieve Life Sciences and Revance Therapeutics among losers\" data-tweet=\"$BIOC $BIOC $PETQ - Biocept leads healthcare gainers; Achieve Life Sciences and Revance Therapeutics among losers https://seekingalpha.com/news/3423527-biocept-leads-healthcare-gainers-achieve-life-sciences-and-revance-therapeutics-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3423527-biocept-leads-healthcare-gainers-achieve-life-sciences-and-revance-therapeutics-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423525\" data-ts=\"1547654200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDIT\" target=\"_blank\">EDIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423525-gene-editors-up-on-promising-research-in-parasitic-diseases\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gene editors up on promising research in parasitic diseases</a></h4><ul><li>Editas Medicine (<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color=\"green\">+3.6%</font>), Intellia Therapeutics (<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color=\"green\">+6.9%</font>) and CRISPR Therapeutics (<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color=\"green\">+3.5%</font>) are all enjoying a modest uptick in buying in apparent response to just-published <a href=\"https://smhs.gwu.edu/news/gene-editing-tool-crisprcas9-shown-limit-impact-certain-parasitic-diseases\" target=\"_blank\">research</a> that gene editing technology CRISPR/Cas9 may be useful in combating certain tropical diseases.</li><li>Scientists at George Washington University, working with international colleagues, used CRISPR/Cas9 to limit the deleterious effects of parasitic worms that cause <a href=\"https://www.who.int/news-room/fact-sheets/detail/schistosomiasis\" target=\"_blank\">schistosomiasis</a> and <a href=\"https://www.cdc.gov/parasites/liver_flukes/index.html\" target=\"_blank\">liver fluke infection</a> by knocking out a certain gene that encodes for an enzyme released by the worms' eggs that damages tissues. The elimination of the protein, called omega-1 ribonuclease, greatly reduced the impact of the disease.</li><li>The diseases, endemic in Southeast Asia, sub-Saharan Africa and Latin America, affect ~250M people.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423525\" data-linked=\"Gene editors up on promising research in parasitic diseases\" data-tweet=\"$EDIT $EDIT $NTLA - Gene editors up on promising research in parasitic diseases https://seekingalpha.com/news/3423525-gene-editors-up-on-promising-research-in-parasitic-diseases?source=tweet\" data-url=\"https://seekingalpha.com/news/3423525-gene-editors-up-on-promising-research-in-parasitic-diseases\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423519\" data-ts=\"1547653050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423519-apple-talks-watch-medicare-plans-cnbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple talks Watch with Medicare plans - CNBC</a></h4><ul><li>Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+1.1%</font>) is talking with at least three private Medicare plans to about getting the Apple Watch to at-risk seniors, according to <a href=\"https://www.cnbc.com/2019/01/15/apple-talking-to-private-medicare-plans-about-subsidizing-apple-watch.html\" target=\"_blank\">CNBC sources</a>.</li><li>The latest model includes fall detection and an electrocardiogram that could benefit seniors, but the $399 price tag means many seniors can't afford it. Apple wants the Medicare plans to offer subsidies.</li><li>Apple has previously made deals with insurers Aetna and United Healthcare about subsidizing the Watch's cost for members.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423519\" data-linked=\"Apple talks Watch with Medicare plans - CNBC\" data-tweet=\"$AAPL - Apple talks Watch with Medicare plans - CNBC https://seekingalpha.com/news/3423519-apple-talks-watch-medicare-plans-cnbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3423519-apple-talks-watch-medicare-plans-cnbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>107&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423517\" data-ts=\"1547652946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NHYDY\" target=\"_blank\">NHYDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423517-norsk-hydro-says-brazilian-state-lifts-embargo-on-alunorte-alumina-refinery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Norsk Hydro says Brazilian state lifts embargo on Alunorte alumina refinery</a></h4><ul><li>Norsk Hydro (<a href='https://seekingalpha.com/symbol/NHYDY' title='Norsk Hydro ASA ADR'>OTCQX:NHYDY</a> <font color='green'>+5.4%</font>) says Brazil's Para state <a href=\"https://www.reuters.com/article/us-norsk-hydro-brazil/norsk-hydro-says-brazil-state-authority-lifts-alunorte-production-embargo-idUSKCN1PA01M\" target=\"_blank\">lifted a production embargo</a> on the company's Alunorte alumina refinery, although full production will not resume until a Brazilian federal  court follows suit.</li><li>Alunorte, the world\u2019s largest alumina refinery, has been operating at half capacity  since early last year after Norsk Hydro admitted making unlicensed emissions  of untreated water during severe rains.</li><li>At full capacity, the plant can produce 6.4M metric tons of alumina, or 10% of the world\u2019s capacity outside China.</li><li>Potentially relevant tickers include <a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a>, <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a>, <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a>, <a href='https://seekingalpha.com/symbol/CSTM' title='Constellium Holdco B.V.'>CSTM</a>, <a href='https://seekingalpha.com/symbol/KALU' title='Kaiser Aluminum Corporation'>KALU</a>, <a href='https://seekingalpha.com/symbol/ACH' title='Aluminum Corporation of China Ltd'>ACH</a>.</li><li>ETF: <a href='https://seekingalpha.com/symbol/JJUB' title='iPath Series B Bloomberg Aluminum Subindex Total Return ETN'>JJUB</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3423517\" data-linked=\"Norsk Hydro says Brazilian state lifts embargo on Alunorte alumina refinery\" data-tweet=\"$NHYDY $NHYDY $AA - Norsk Hydro says Brazilian state lifts embargo on Alunorte alumina refinery https://seekingalpha.com/news/3423517-norsk-hydro-says-brazilian-state-lifts-embargo-on-alunorte-alumina-refinery?source=tweet\" data-url=\"https://seekingalpha.com/news/3423517-norsk-hydro-says-brazilian-state-lifts-embargo-on-alunorte-alumina-refinery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423516\" data-ts=\"1547652663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423516-crude-inventory-declines-in-last-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude inventory declines in the last week</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>-2.7M </strong>barrels vs. -1.3M consensus, -1.7M last week.</li><li>Gasoline<strong> +7.5M</strong> barrels vs. +2.8M consensus, +8.1M last week.</li><li>Distillates <strong>+3.0M </strong>barrels vs. +1.6M consensus, +10.6M last week.</li><li>Futures <font color=\"green\">+0.10%</font> to $52.16.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423516\" data-linked=\"Crude inventory declines in the last week\" data-tweet=\"$USO $OIL $UCO - Crude inventory declines in the last week https://seekingalpha.com/news/3423516-crude-inventory-declines-in-last-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3423516-crude-inventory-declines-in-last-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423513\" data-ts=\"1547652559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423513-biocept-up-26-ahead-of-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept up 26% ahead of equity offering</a></h4><ul><li>Nano cap Biocept (<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color=\"green\">+25.7%</font>) is up on double normal volume. Shares have more than doubled this week.</li><li>A month ago, it filed a <a href=\"https://seekingalpha.com/news/3418116-biocept-readies-downsized-equity-offering-shares-12-percent-premarket\" target=\"_blank\">prospectus</a> for a public offering of ~5.3M common shares and warrants.</li><li>At the end of September 2018, it had $2.1M in cash while operations consumed $13.9M during the first three quarters of the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423513\" data-linked=\"Biocept up 26% ahead of equity offering\" data-tweet=\"$BIOC - Biocept up 26% ahead of equity offering https://seekingalpha.com/news/3423513-biocept-up-26-ahead-of-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3423513-biocept-up-26-ahead-of-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423510\" data-ts=\"1547652397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAL\" target=\"_blank\">UAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423510-united-and-peers-in-rally-mode\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United and peers in rally mode</a></h4><ul> <li>United Continental (<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a> <font color='green'>+7%</font>) is giving the airline sector the lift it needed after posting 2019 profit guidance ahead of expectations.</li> <li>The strong results could be enough to take the spotlight off the short-term hit to revenue from the large amount of government/contractor travel that has been canceled this month.</li> <li>Gainers include Delta Air Lines (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color='green'>+1.2%</font>), Southwest Airlines (<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a> <font color='green'>+1.7%</font>), JetBlue (<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a> <font color='green'>+1.4%</font>), Southwest Airlines (<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a> <font color='green'>+1.7%</font>), Spirit Airlines (<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a> <font color='green'>+4%</font>), Mesa Air (<a href='https://seekingalpha.com/symbol/MESA' title='Mesa Air Group'>MESA</a> <font color='green'>+3.9%</font>), Hawaiian Holdings (<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a> <font color='green'>+2.5%</font>), Alaska Air (<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a> <font color='green'>+1.2%</font>), Allegiant Travel (<a href='https://seekingalpha.com/symbol/ALGT' title='Allegiant Travel Company'>ALGT</a> <font color='green'>+2.5%</font>) and SkyWest (<a href='https://seekingalpha.com/symbol/SKYW' title='SkyWest, Inc.'>SKYW</a> <font color='green'>+1.1%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3423286-united-continental-plus-5-percent-posting-strong-quarter\" target=\"_blank\">United Continental +5% after posting strong quarter</a> (Jan. 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423510\" data-linked=\"United and peers in rally mode\" data-tweet=\"$UAL $UAL $DAL - United and peers in rally mode https://seekingalpha.com/news/3423510-united-and-peers-in-rally-mode?source=tweet\" data-url=\"https://seekingalpha.com/news/3423510-united-and-peers-in-rally-mode\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423509\" data-ts=\"1547651902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOGO\" target=\"_blank\">GOGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423509-gogo-installed-477-net-aircraft-in-2018-sharesplus-2_6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gogo installed 477 net aircraft in 2018; shares +2.6%</a></h4><ul>   <li>Gogo (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a>) is <font color=\"green\">up 2.6%</font> after its 2018 update, where it announced <a href=\"https://seekingalpha.com/pr/17381892-gogo-reaches-approximately-1300-commercial-aircraft-installed-satellite-ifc-technology\" target=\"_blank\">installation of a net 477 aircraft</a> with satellite technology, the second straight year over 450.</li>    <li>At year-end the company had 1,296 net commercial aircraft installed with in-flight connectivity.</li>    <li>That includes 1,007 aircraft installed and activated with 2Ku technology; 252 aircraft on line with Ku technology; and 37 aircraft installed with 2Ku but not yet recorded as Aircraft Online.</li>    <li>It also has about 1,000 2Ku aircraft in backlog.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423509\" data-linked=\"Gogo installed 477 net aircraft in 2018; shares +2.6%\" data-tweet=\"$GOGO - Gogo installed 477 net aircraft in 2018; shares +2.6% https://seekingalpha.com/news/3423509-gogo-installed-477-net-aircraft-in-2018-sharesplus-2_6?source=tweet\" data-url=\"https://seekingalpha.com/news/3423509-gogo-installed-477-net-aircraft-in-2018-sharesplus-2_6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423492\" data-ts=\"1547650291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMTA\" target=\"_blank\">SMTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423492-spirit-mta-surges-8_7-after-speeding-up-strategic-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spirit MTA surges 8.7% after speeding up strategic review</a></h4><ul><li>Spirit MTA REIT (NYSE:<a href='https://seekingalpha.com/symbol/SMTA' title='Spirit MTA REIT'>SMTA</a>) <font color=\"green\">jumps 8.7%</font> after the REIT's board decides to <a href=\"https://seekingalpha.com/pr/17382377-spirit-mta-reit-accelerates-strategic-plan\" target=\"_blank\">speed up its strategic plan </a>and hires advisers to explore ways to maximize shareholder value.</li><li>Strategic alternatives to be considered may include a sale of the company or the Master Trust 2014, a merger, or other potential alternatives.</li><li>\"Through the acceleration of our strategic plan, we will explore all available options to maximize shareholder value,\" says SMTA CEO, CFO and Treasurer Ricardo Rodriguez. \"Our board of trustees also intends to continue paying dividends equal to 100% of CAD.\u201d</li><li>As of Sept. 30, 2018, SMTA\u2019s portfolio of assets consisted of 784 properties held through the Master Trust 2014, including 5 assets leased to ShopKo Stores.</li><li>SMTA continues to monitor its ShopKo Stores-related assets, including in connection with the filing by ShopKo Stores and its affiliates of petitions for relief under Chapter 11 on Jan. 16, 2019.</li><li>SMTA doesn't expect to get any additional cash flow going forward from any of the assets leased to ShopKo Stores, nor bear further meaningful expenses related to those assets.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3408059-spirit-mta-reit-q3-adjusted-ebitdare-rises-3-percent-y-y\" target=\"_blank\">More on Spirit MTA REIT Q3: Adjusted EBITDAre rises 3% Y/Y</a> (Nov. 9, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3423492\" data-linked=\"Spirit MTA surges 8.7% after speeding up strategic review\" data-tweet=\"$SMTA - Spirit MTA surges 8.7% after speeding up strategic review https://seekingalpha.com/news/3423492-spirit-mta-surges-8_7-after-speeding-up-strategic-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3423492-spirit-mta-surges-8_7-after-speeding-up-strategic-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423486\" data-ts=\"1547649722\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INPX\" target=\"_blank\">INPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423486-inpixonplus-17-on-sas-collab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inpixon +17% on SAS collab</a></h4><ul><li>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) announces a tech integration collaboration with advanced analytics software company SAS.</li><li>SAS will integrate INPX's Indoor Positioning Analytics and metrics into its dashboard and analytics.</li><li>Inpixon also joins the SAS IoT Eco-system Program, and the companies plan joint marketing and promotional activities.</li><li>INPX is <font color=\"green\">up 17.2%</font> to $2.73.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423486\" data-linked=\"Inpixon +17% on SAS collab\" data-tweet=\"$INPX - Inpixon +17% on SAS collab https://seekingalpha.com/news/3423486-inpixonplus-17-on-sas-collab?source=tweet\" data-url=\"https://seekingalpha.com/news/3423486-inpixonplus-17-on-sas-collab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423485\" data-ts=\"1547649653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHW\" target=\"_blank\">SCHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423485-schwabplus-3_1-q4-benefits-from-client-cash-allocations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schwab +3.1% as Q4 benefits from client cash allocations</a></h4><ul><li>Charles Schwab Corp. (NYSE:<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a>) <font color=\"green\">gains 3.1% </font>after<a href=\"https://seekingalpha.com/pr/17382189-schwab-fourth-quarter-net-income-935-million-caps-record-year\" target=\"_blank\"> Q4 EPS</a> benefits from a surge in client cash allocations in December.</li><li>Q4 EPS of 65 cents beats the average analyst estimate of 64 cents and revenue of $2.67B beats consensus of $2.63B.</li><li>Q4 EPS increased from 41 cents a year ago and revenue rose 19% Y/Y.</li><li>\"We grew our consolidated balance sheet 22% to end the year at $297B, reflecting client cash allocations through the year \u2013 including a December surge in the midst of heightened market volatility \u2013 and $72B of sweep transfers,\" CFO Peter Crawford said, commenting on 2018 results.</li><li>Total assets grew 9% during the quarter to $296.5B from $272.1B.</li><li>Net interest revenue increased 42% $1.63B from $1.15B a year ago, asset management and administration fees fell 13% to $755M from $863M, and trading revenue rose 34% to $206M from $154M.</li><li>Q4 return on average common stockholders' equity rose to 20% (annualized) from 14% a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3423446-charles-schwab-beats-0_01-beats-revenue\" target=\"_blank\">Charles Schwab beats by $0.01, beats on revenue</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3423485\" data-linked=\"Schwab +3.1% as Q4 benefits from client cash allocations\" data-tweet=\"$SCHW - Schwab +3.1% as Q4 benefits from client cash allocations https://seekingalpha.com/news/3423485-schwabplus-3_1-q4-benefits-from-client-cash-allocations?source=tweet\" data-url=\"https://seekingalpha.com/news/3423485-schwabplus-3_1-q4-benefits-from-client-cash-allocations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423482\" data-ts=\"1547649180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HBM\" target=\"_blank\">HBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423482-hudbay-minerals-in-proxy-fight-waterton-seeks-to-replace-board-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hudbay Minerals in proxy fight as Waterton seeks to replace board, CEO</a></h4><ul><li>P-E firm Waterton Global Resource Management <a href=\"https://www.wsj.com/articles/waterton-seeks-to-replace-board-ceo-at-canadian-miner-hudbay-11547647291\" target=\"_blank\">launches a proxy fight</a> with Hudbay Minerals (<a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc Ordinary Sh'>HBM</a> <font color=\"green\">+2.6%</font>), announcing <a href=\"https://seekingalpha.com/pr/17382244-waterton-announces-eight-fully-independent-director-nominees-election-hudbay-minerals-board\" target=\"_blank\">eight director candidates for election</a> to the company\u2019s 10-member board.</li><li>Waterton, which owns an 11.9% stake in HBM, also wants to bring on former Nevsun Resources CEO Peter Kukielski as HBM's new CEO and board member; he resigned last month as Nevsun was acquired by a China's Zijin Mining.</li><li>Waterton says HBM has \"repeatedly failed to realize its potential\" due to a culture of entrenchment, weak leadership and the need for more board members with experience in South America, where the company has mining operations.</li><li>The P-E firm first announced its intention to nominate a majority slate of candidates to the board <a href=\"https://seekingalpha.com/news/3416903-waterton-plans-nominate-majority-slate-hudbay-minerals-board\" target=\"_blank\">in December</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423482\" data-linked=\"Hudbay Minerals in proxy fight as Waterton seeks to replace board, CEO\" data-tweet=\"$HBM - Hudbay Minerals in proxy fight as Waterton seeks to replace board, CEO https://seekingalpha.com/news/3423482-hudbay-minerals-in-proxy-fight-waterton-seeks-to-replace-board-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3423482-hudbay-minerals-in-proxy-fight-waterton-seeks-to-replace-board-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423480\" data-ts=\"1547648965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSO\" target=\"_blank\">PSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423480-pearsonminus-6_6-on-trading-update-2018-profits-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pearson -6.6% on trading update; 2018 profits in line</a></h4><ul>   <li>Pearson (NYSE:<a href='https://seekingalpha.com/symbol/PSO' title='Pearson plc'>PSO</a>) is <font color=\"red\">6.6% lower</font> premarket after <a href=\"https://www.pearson.com/corporate/news/media/news-announcements/2019/01/pearson-january-trading-update--unaudited-.html\" target=\"_blank\">announcing</a> it sees fiscal 2018 adjusted operating profit coming in at £540M-£545M, in line with its guidance of £520M-£560M.</li>    <li>EPS is seen at 70-71 pence, with total underlying revenues down 1% Y/Y, paced by declines in U.S. Higher Education Courseware and U.S. K12 Courseware.</li>    <li>Revenue in North America fell 1%, the company says; Core flat; and Growth up 1%.</li>    <li>For 2019, it expects to deliver adjusted operating profit of £590M-£640M, with U.S. Higher Ed Courseware revenue flat to down 5% as \"underlying pressures continue,\" with the rest of the business showing aggregate growth.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423480\" data-linked=\"Pearson -6.6% on trading update; 2018 profits in line\" data-tweet=\"$PSO - Pearson -6.6% on trading update; 2018 profits in line https://seekingalpha.com/news/3423480-pearsonminus-6_6-on-trading-update-2018-profits-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3423480-pearsonminus-6_6-on-trading-update-2018-profits-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423477\" data-ts=\"1547648893\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFII\" target=\"_blank\">EFII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423477-electronics-for-imaging-gets-street-low-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Electronics For Imaging gets Street-low target</a></h4><ul><li>Morgan Stanley analyst Katy Huberty maintains an Overweight rating on Electronics For Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a>) and lowers the target from $28 to the Street-low $20.</li><li>Huberty cites yesterday's downside<a href=\"https://seekingalpha.com/news/3423276-efi-reports-downside-preliminary-guidance\" target=\"_blank\"> preliminary guidance</a>, which came with macro concerns and \"dependence on back-end loaded revenue.\"</li><li>The analyst cuts 2019 revenue and EPS estimates by 5% and 14%, respectively.</li><li>Source: Bloomberg First Word.</li><li>EFII shares are <font color=\"red\">down 26%</font> premarket to $20.14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423477\" data-linked=\"Electronics For Imaging gets Street-low target\" data-tweet=\"$EFII - Electronics For Imaging gets Street-low target https://seekingalpha.com/news/3423477-electronics-for-imaging-gets-street-low-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3423477-electronics-for-imaging-gets-street-low-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423473\" data-ts=\"1547648657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TBLT\" target=\"_blank\">TBLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423473-bac-ual-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAC, UAL among premarket gainers</a></h4><ul><li>ToughBuilt (NASDAQ:<a href='https://seekingalpha.com/symbol/TBLT' title='ToughBuilt Industries, Inc.'>TBLT</a>) <font color=\"green\">+191%</font> on <a href=\"https://seekingalpha.com/pr/17381970-toughbuilt-launches-sales-menards-home-improvement-chain\" target=\"_blank\">launching</a> product sales following an earlier distribution agreement with Menards.</li><li>Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a>) <font color=\"green\">+22%</font>.</li><li>Pain Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a>) <font color=\"green\">+22%</font> as Massachusetts AG after Purdue Pharma owners for role in <a href=\"https://seekingalpha.com/news/3423408-massachusetts-ag-purdue-pharma-owners-role-opioid-crisis\" target=\"_blank\">opioid crisis</a>.</li><li>First Data (NYSE:<a href='https://seekingalpha.com/symbol/FDC' title='First Data Corporation'>FDC</a>) <font color=\"green\">+19%</font> on preliminary <a href=\"https://seekingalpha.com/news/3423428-first-data-sees-fy-2018-revenue-high-9_5b\" target=\"_blank\">revenue</a>.</li><li>Viveve Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>) <font color=\"green\">+14%</font> on prelim <a href=\"https://seekingalpha.com/news/3423445-viveve-sees-fy-2018-revenue-high-18_5m-shares-21-percent-premarket\" target=\"_blank\">revenue</a>.</li><li>China Ceramics (NASDAQ:<a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a>) <font color=\"green\">+13%</font>.</li><li>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"green\">+9%</font> on technology integration <a href=\"https://seekingalpha.com/pr/17382122-inpixon-sas-collaborate-deliver-advanced-analytics-internet-things-iot\" target=\"_blank\">collaboration</a> with SAS and</li><li>CLPS (NASDAQ:<a href='https://seekingalpha.com/symbol/CLPS' title='CLPS, Inc'>CLPS</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/pr/17381880-clps-incorporations-blockchain-passes-university-testing\" target=\"_blank\">update</a> on its most recent blockchain research and development efforts.</li><li>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines'>VBIV</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/news/3423400-oppenheimer-likes-vbi-vaccines-premarket-analyst-action\" target=\"_blank\">upgrade</a>.</li><li>Ability (NASDAQ:<a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a>) <font color=\"green\">+8%</font>.</li><li>United Continental Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a>) <font color=\"green\">+6%</font> on Q4 <a href=\"https://seekingalpha.com/news/3423264-united-continental-beats-0_45-beats-revenue\" target=\"_blank\">earnings</a>.</li><li>Bank of America (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>) <font color=\"green\">+6%</font> on Q4 <a href=\"https://seekingalpha.com/news/3423378-bank-america-beats-0_07-beats-revenue\" target=\"_blank\">earnings</a>.</li><li>Tyme Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TYME' title='Tyme Technologies, Inc.'>TYME</a>) <font color=\"green\">+4%</font>.</li><li>China Advanced Construction Materials  (NASDAQ:<a href='https://seekingalpha.com/symbol/CADC' title='China Advanced Construction Materials Group, Inc.'>CADC</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/news/3423359-china-advanced-construction-materials-regains-compliance-nasdaq\" target=\"_blank\">regaining</a> compliance with Nasdaq.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423473\" data-linked=\"BAC, UAL among premarket gainers\" data-tweet=\"$TBLT $TBLT $MBOT - BAC, UAL among premarket gainers https://seekingalpha.com/news/3423473-bac-ual-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3423473-bac-ual-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423469\" data-ts=\"1547648351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTIE\" target=\"_blank\">PTIE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423469-pain-therapeutics-up-13-on-receiving-1_5m-grant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pain Therapeutics up 13% on receiving $1.5M grant</a></h4><ul><li>Pain Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a>) has been <a href=\"https://seekingalpha.com/pr/17382291-pain-therapeutics-awarded-1_5-million-research-grant-national-institutes-health\" target=\"_blank\">awarded</a> $1.5M in research funding from the National Institutes of Health to support development of new technology for Alzheimer\u2019s disease with a simple blood test.</li>     <li>Shares are up <font color=\"green\">13%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3423469\" data-linked=\"Pain Therapeutics up 13% on receiving $1.5M grant\" data-tweet=\"$PTIE $SAVA - Pain Therapeutics up 13% on receiving $1.5M grant https://seekingalpha.com/news/3423469-pain-therapeutics-up-13-on-receiving-1_5m-grant?source=tweet\" data-url=\"https://seekingalpha.com/news/3423469-pain-therapeutics-up-13-on-receiving-1_5m-grant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423467\" data-ts=\"1547648315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEZS\" target=\"_blank\">AEZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423467-aeterna-zentaris-macimorelin-okd-in-europe-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aeterna Zentaris&#39; macimorelin OK&#39;d in Europe; shares up 1% premarket</a></h4><ul><li>Aeterna Zentaris (NASDAQ:<a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a>) is up <font color=\"green\">1%</font> premarket on light volume following the <a href=\"https://seekingalpha.com/pr/17382361-aeterna-zentaris-receives-european-marketing-clearance-macimorelin\" target=\"_blank\">approval </a>in Europe of macimorelin for diagnosis of adult growth hormone deficiency. Two months ago, the advisory group CHMP adopted a positive opinion backing authorization.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423467\" data-linked=\"Aeterna Zentaris&#39; macimorelin OK&#39;d in Europe; shares up 1% premarket\" data-tweet=\"$AEZS - Aeterna Zentaris&#39; macimorelin OK&#39;d in Europe; shares up 1% premarket https://seekingalpha.com/news/3423467-aeterna-zentaris-macimorelin-okd-in-europe-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3423467-aeterna-zentaris-macimorelin-okd-in-europe-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423462\" data-ts=\"1547647984\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTX\" target=\"_blank\">APTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423462-fisv-snap-and-aptx-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FISV, SNAP and APTX among premarket losers</a></h4><ul><li>Aptinyx (NASDAQ:<a href='https://seekingalpha.com/symbol/APTX' title='Aptinyx'>APTX</a>) <font color=\"red\">-66%</font> on <a href=\"https://seekingalpha.com/news/3423416-aptinyx-63-percent-premarket-failed-clinical-trial\" target=\"_blank\">failed</a> clinical trial.</li><li>Electronics for Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a>) <font color=\"red\">-26%</font> on <a href=\"https://seekingalpha.com/news/3423276-efi-reports-downside-preliminary-guidance\" target=\"_blank\">downside</a> preliminary guidance.</li><li>Kitov Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a>) <font color=\"red\">-16%</font>.</li><li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) <font color=\"red\">-12%</font> after CFO <a href=\"https://seekingalpha.com/news/3423321-snap-minus-4_9-percent-cfo-resigns\" target=\"_blank\">resigns</a>.</li><li>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"red\">-9%</font>.</li><li>Nordstrom (NYSE:<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>) <font color=\"red\">-8%</font> on holiday sales and <a href=\"https://seekingalpha.com/news/3423330-nordstrom-minus-2_8-percent-holiday-sales-guidance\" target=\"_blank\">guidance</a>.</li><li>Blue Apron Holdings (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>) <font color=\"red\">-7%</font>.</li><li>VirnetX Holding (NYSEMKT:<a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a>) <font color=\"red\">-8%</font>.</li><li>Hexindai (NASDAQ:<a href='https://seekingalpha.com/symbol/HX' title='Hexindai Inc.'>HX</a>) <font color=\"red\">-7%</font>.</li><li>Pearson (NYSE:<a href='https://seekingalpha.com/symbol/PSO' title='Pearson plc'>PSO</a>) <font color=\"red\">-7%</font>.</li><li>Fiserv (NASDAQ:<a href='https://seekingalpha.com/symbol/FISV' title='Fiserv, Inc.'>FISV</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3423396-m-animal-spirits-hit-payments-fiserv-first-data-merge\" target=\"_blank\">merger</a> with First Data.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423462\" data-linked=\"FISV, SNAP and APTX among premarket losers\" data-tweet=\"$APTX $APTX $EFII - FISV, SNAP and APTX among premarket losers https://seekingalpha.com/news/3423462-fisv-snap-and-aptx-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3423462-fisv-snap-and-aptx-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423453\" data-ts=\"1547647504\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGSE\" target=\"_blank\">RGSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423453-rgs-energys-powerhouse-solar-shingle-wins-california-commission-ok\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RGS Energy&#39;s Powerhouse solar shingle wins California Commission OK</a></h4><ul><li>RGS Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a>) <font color=\"green\">+7.3%</font> pre-market after saying the California Energy Commission <a href=\"https://seekingalpha.com/pr/17382151-rgs-energy-s-powerhouse-solar-shingle-system-receives-california-clean-energy-commission\" target=\"_blank\">approved</a> the company's Powerhouse 3.0 solar shingle system and added it to the commission\u2019s list of Eligible Photovoltaic Modules.</li><li>The regulatory approval allows RGSE to sell the Powerhouse product in California, the largest U.S. solar market.</li><li>RGSE says it has successfully manufactured its first solar  shingles and are now available for shipment, and has started accepting purchase  orders for Powerhouse 3.0.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423453\" data-linked=\"RGS Energy&#39;s Powerhouse solar shingle wins California Commission OK\" data-tweet=\"$RGSE - RGS Energy&#39;s Powerhouse solar shingle wins California Commission OK https://seekingalpha.com/news/3423453-rgs-energys-powerhouse-solar-shingle-wins-california-commission-ok?source=tweet\" data-url=\"https://seekingalpha.com/news/3423453-rgs-energys-powerhouse-solar-shingle-wins-california-commission-ok\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423446\" data-ts=\"1547647192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHW\" target=\"_blank\">SCHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423446-charles-schwab-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charles Schwab beats by $0.01, beats on revenue</a></h4><ul><li>Charles Schwab (NYSE:<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a>): Q4 GAAP EPS of $0.65 <span style=\"color:green\">beats by $0.01</span>.</li><li>Revenue of $2.67B (+19.2% Y/Y) <font color=\"green\">beats by $40M</font>.</li><li>Shares <font color=\"green\">+1.69%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17382189-schwab-fourth-quarter-net-income-935-million-caps-record-year\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3423446\" data-linked=\"Charles Schwab beats by $0.01, beats on revenue\" data-tweet=\"$SCHW - Charles Schwab beats by $0.01, beats on revenue https://seekingalpha.com/news/3423446-charles-schwab-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3423446-charles-schwab-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423445\" data-ts=\"1547647083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVE\" target=\"_blank\">VIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423445-viveve-sees-fy-2018-revenue-high-18_5m-shares-up-21-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viveve sees FY 2018 revenue as high as $18.5M; shares up 21% premarket</a></h4><ul> <li>Viveve Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>) <a href=\"https://seekingalpha.com/pr/17382089-viveve-reports-preliminary-full-year-2018-financial-results-announces-2019-revenue-guidance\" target=\"_blank\">reports</a> preliminary Q4 and FY 2018 revenue of ~$4.4M and ~$18.5M, respectively.</li>    <li><strong>2019 milestones</strong></li><li>Completion of study enrollment in VIVEVE II for sexual function;</li><li>Release of final data from LIBERATE-International in SUI and achievement of regulatory clearance; and</li><li>Approval of the IDE from FDA to conduct the LIBERATE-U.S. trial in SUI.</li>            <li>Also, the board of directors has appointed Steven Basta, to the position of Chairman.</li><li>The company plans to report its final results in March 2019.</li><li>Shares are up <font color=\"green\">21%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3423445\" data-linked=\"Viveve sees FY 2018 revenue as high as $18.5M; shares up 21% premarket\" data-tweet=\"$VIVE $VIVMD - Viveve sees FY 2018 revenue as high as $18.5M; shares up 21% premarket https://seekingalpha.com/news/3423445-viveve-sees-fy-2018-revenue-high-18_5m-shares-up-21-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3423445-viveve-sees-fy-2018-revenue-high-18_5m-shares-up-21-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423441\" data-ts=\"1547646386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PNC\" target=\"_blank\">PNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423441-pnc-q4-misses-nii-declines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PNC Q4 misses as NII declines</a></h4><ul><li>PNC Financial Services (NYSE:<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a>) slips <font color=\"red\">1.0%</font> in premarket trading <a href=\"https://seekingalpha.com/pr/17381801-pnc-reports-full-year-2018-net-income-5_3-billion-10_71-diluted-eps\" target=\"_blank\">after Q4 EPS</a> of $2.75 misses consensus estimate by 4 cents.</li><li>Q4 net interest income of $1.86B falls from $1.89B in Q3 and $1.92B in Q4; net interest margin of 2.96% compares with 2.99% in Q3 and 2.88% in Q4 2017.</li><li>Q4 total revenue of $4.34B slips from $4.36B in Q3 and is up from $4.26B in the year-ago quarter; falls short of consensus by $60M.</li><li>Q4 average loans of $225.9B rose 1% from Q3 and by 2% Y/Y.</li><li>Q4 provision for credit losses $148M vs. $88M in Q3 and $125M in Q4 2017.</li><li>Return on average common equity 11.83% vs. 12.32% in Q3 and 18.90% in Q4 2017.</li><li>Book value per common share of $95.72 at Q4 end vs. $93.22 at Q3 end.</li><li><a href=\"http://www.pnc.com/investorevents\" target=\"_blank\">Conference call</a> 10 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3423382-pnc-financial-misses-0_04-misses-revenue\" target=\"_blank\">PNC Financial misses by $0.04, misses on revenue</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3423441\" data-linked=\"PNC Q4 misses as NII declines\" data-tweet=\"$PNC - PNC Q4 misses as NII declines https://seekingalpha.com/news/3423441-pnc-q4-misses-nii-declines?source=tweet\" data-url=\"https://seekingalpha.com/news/3423441-pnc-q4-misses-nii-declines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423439\" data-ts=\"1547646225\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSS\" target=\"_blank\">TSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423439-payments-sector-mulls-fiserv-first-data-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Payments sector mulls Fiserv/First Data merger</a></h4><ul><li>Fiserv and First Data <a href=\"https://seekingalpha.com/news/3423396-m-animal-spirits-hit-payments-fiserv-first-data-merge\" target=\"_blank\">earlier announced a</a> near-$23B all-stock merger deal, and First Data is <font color=\"green\">up 18%</font> on the news.</li><li>This could spark more M&amp;A in the payments sector, says KBW, which adds that Total Systems Services (NYSE:<a href='https://seekingalpha.com/symbol/TSS' title='Total System Services, Inc.'>TSS</a>) has a model closest to First Data. TSS is <font color=\"green\">up 0.5%</font> premarket.</li><li>Also worth keeping an eye on would be ACI Worldwide (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIW' title='ACI Worldwide, Inc.'>ACIW</a>), Global Payments (NYSE:<a href='https://seekingalpha.com/symbol/GPN' title='Global Payments Inc.'>GPN</a>), Worldpay (NYSE:<a href='https://seekingalpha.com/symbol/WP' title='Worldpay, Inc.'>WP</a>), and even PayPal (NASDAQ:<a href='https://seekingalpha.com/symbol/PYPL' title='PayPal Holdings, Inc.'>PYPL</a>) and Square (NYSE:<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3423439\" data-linked=\"Payments sector mulls Fiserv/First Data merger\" data-tweet=\"$TSS $TSS $ACIW - Payments sector mulls Fiserv/First Data merger https://seekingalpha.com/news/3423439-payments-sector-mulls-fiserv-first-data-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3423439-payments-sector-mulls-fiserv-first-data-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423431\" data-ts=\"1547645180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BK\" target=\"_blank\">BK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423431-bank-of-new-york-mellon-q4-auc-slips-1-to-33_1t\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank of New York Mellon Q4: AUC/A slips by 1% to $33.1T</a></h4><ul><li>Bank of New York Mellon (NYSE:<a href='https://seekingalpha.com/symbol/BK' title='The Bank of New York Mellon Corporation'>BK</a>)<a href=\"https://seekingalpha.com/pr/17381784-bny-mellon-reports-fourth-quarter-2018-earnings-832-million-0_84-per-common-share\" target=\"_blank\"> Q4 adjusted EPS </a>of 99 cents increases from 91 cents a year ago; beats consensus by 7 cents.</li><li>BK <font color=\"green\">+0.7%</font> in premarket trading.</li><li>Q4 total revenue of $4.0B fell 1%, when excluding notable items; misses consensus by $20M.</li><li>Assets under custody and/or administration of $33.1T decreased by 1%, primarily reflecting lower market values and the unfavorable impact of a stronger dollar, partly offset by net new business.</li><li>Assets under management of $1.7T decreased 9%, primarily reflecting the unfavorable impact of a stronger U.S. dollar, lower market values, net outflows, the divestiture of CenterSquare Investment Management, and other changes.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3423373-bank-new-york-mellon-beats-0_07-misses-revenue\" target=\"_blank\">Bank of New York Mellon beats by $0.07, misses on revenue</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3423431\" data-linked=\"Bank of New York Mellon Q4: AUC/A slips by 1% to $33.1T\" data-tweet=\"$BK - Bank of New York Mellon Q4: AUC/A slips by 1% to $33.1T https://seekingalpha.com/news/3423431-bank-of-new-york-mellon-q4-auc-slips-1-to-33_1t?source=tweet\" data-url=\"https://seekingalpha.com/news/3423431-bank-of-new-york-mellon-q4-auc-slips-1-to-33_1t\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423428\" data-ts=\"1547644782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDC\" target=\"_blank\">FDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423428-first-data-sees-fy-2018-revenue-high-9_5b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First Data sees FY 2018 revenue as high as $9.5B</a></h4><ul> <li>First Data (NYSE:<a href='https://seekingalpha.com/symbol/FDC' title='First Data Corporation'>FDC</a>) <a href=\"https://seekingalpha.com/pr/17381865-first-data-reports-preliminary-fourth-quarter-full-year-2018-financial-results-preliminary\" target=\"_blank\">reports</a>       preliminary Q4 and FY 2018 results and 2019 guidance.</li>     <li><strong>Preliminary Q4 and FY 2018 results</strong></li>     <li>Q4 and FY total revenue of ~$2.4B and $9.5B,       respectively.</li>          <li>Q4 and FY GAAP EPS of ~$0.17 and ~$1.05, respectively.</li><li>Q4 and FY Non-GAAP EPS of ~$0.38 and ~$1.41, respectively.</li>     <li><strong>Preliminary FY 2019 guidance</strong></li>     <li>Organic constant       currency revenue growth in the range of 5% to 6%.       Non-GAAP EPS growth is expected in the low double digits.</li><li>Final Q4 and FY 2018 results will be provided on February 7.</li><li>Shares are up <font color=\"green\">20%</font> premarket.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3423428\" data-linked=\"First Data sees FY 2018 revenue as high as $9.5B\" data-tweet=\"$FDC - First Data sees FY 2018 revenue as high as $9.5B https://seekingalpha.com/news/3423428-first-data-sees-fy-2018-revenue-high-9_5b?source=tweet\" data-url=\"https://seekingalpha.com/news/3423428-first-data-sees-fy-2018-revenue-high-9_5b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423416\" data-ts=\"1547644555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTX\" target=\"_blank\">APTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423416-aptinyx-down-63-premarket-on-failed-clinical-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptinyx down 63% premarket on failed clinical trial</a></h4><ul><li>Thinly traded small cap Aptinyx (NASDAQ:<a href='https://seekingalpha.com/symbol/APTX' title='Aptinyx'>APTX</a>) is down <font color=\"red\">63% </font>premarket on light volume following its <a href=\"https://seekingalpha.com/pr/17381875-aptinyx-reports-top-line-results-phase-2-clinical-study-nyxminus-2925-painful-diabetic\" target=\"_blank\">announcement </a>that a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03219320?lead=aptinyx&amp;rank=2\" target=\"_blank\">Phase 2 clinical trial</a> evaluating lead candidate NYX-2925 in patients with painful diabetic peripheral neuropathy &#40;DPN&#41; failed to achieve the primary endpoint. Specifically, NYX-2925 failed to sufficiently separate from placebo as measured by average daily pain scores versus baseline.</li><li>The results will be submitted for presentation at an upcoming medical meeting.</li><li>The company says it will decide on a path forward once it completes the data analysis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423416\" data-linked=\"Aptinyx down 63% premarket on failed clinical trial\" data-tweet=\"$APTX - Aptinyx down 63% premarket on failed clinical trial https://seekingalpha.com/news/3423416-aptinyx-down-63-premarket-on-failed-clinical-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3423416-aptinyx-down-63-premarket-on-failed-clinical-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423424\" data-ts=\"1547643984\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMA\" target=\"_blank\">CMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423424-comerica-beats-0_08-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comerica beats by $0.08, misses on revenue</a></h4><ul><li>Comerica (NYSE:<a href='https://seekingalpha.com/symbol/CMA' title='Comerica Inc.'>CMA</a>): Q4 Non-GAAP EPS of $1.95 <span style=\"color:green\">beats by $0.08</span>; GAAP EPS of $1.88 <span style=\"color:green\">beats by $0.01</span>.</li><li>Revenue of $864M (+4.1% Y/Y) <font color=\"red\">misses by $0.97M</font>.</li><li>Shares <font color=\"green\">+1.85%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17382051-comerica-reports-fourth-quarter-2018-earnings-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3423424\" data-linked=\"Comerica beats by $0.08, misses on revenue\" data-tweet=\"$CMA - Comerica beats by $0.08, misses on revenue https://seekingalpha.com/news/3423424-comerica-beats-0_08-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3423424-comerica-beats-0_08-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423419\" data-ts=\"1547643745\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423419-goldman-sachsplus-3_0-after-q4-blowout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs +3.0% after Q4 blowout</a></h4><ul><li>Goldman Sachs (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>)<font color=\"green\"> rises 3.0%</font> in premarket trading after <a href=\"https://www.goldmansachs.com/media-relations/press-releases/current/pdfs/2018-q4-results.pdf\" target=\"_blank\">Q4 EPS of $6.04</a> blows away the average analyst estimate of $4.30 as net interest income rose and operating expenses and income taxes declined.</li><li>Q4 net interest income of $991M increased 16% from Q3 and 10% from the year-ago quarter.</li><li>Operating expenses of $5.15B fell 8% from Q3 and rose 9% from a year ago; provision for income taxes fell to $170M from $554M in Q3 and $5.04B in Q4 2017.</li><li>Q4 net revenue of $8.08B, down 8% from Q3 and unchanged from a year ago; exceeds consensus by $580M.</li><li>Q4 provision for credit losses of $222M compared with $174M in Q3 and $290M in the year-ago quarter.</li><li>Return on average common shareholders' equity ws 12.1% for Q4.</li><li>Investment Banking net revenue of $2.04B, up 3% from Q3 and down 5% from Q4 2017.</li><li>Institution Client Services net revenue of $2.43B fell 22% from Q3 and up 2% from Q4 2017; FICC client execution net revenue of $822M fell 18% Y/Y; equities net revenue of $1.60B rose 17% Y/Y.</li><li>Investing &amp; Lending net revenue of $1.91B fell 6% from Q3 and down 2% from Q4 2017.</li><li>Investment Management net revenue of $1.70B was unchanged from Q3 and up 2% from Q4 2017.</li><li>Total assets were $933B as of Dec. 31, 2018, down from $957B as of Sept. 30, 2018.</li><li>Book value per common share was $207.36 at Dec. 31, 2018.</li><li><a href=\"http://www.goldmansachs.com/investor-relations\" target=\"_blank\">Conference call</a> at 9:30 AM ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423419\" data-linked=\"Goldman Sachs +3.0% after Q4 blowout\" data-tweet=\"$GS - Goldman Sachs +3.0% after Q4 blowout https://seekingalpha.com/news/3423419-goldman-sachsplus-3_0-after-q4-blowout?source=tweet\" data-url=\"https://seekingalpha.com/news/3423419-goldman-sachsplus-3_0-after-q4-blowout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423406\" data-ts=\"1547642371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423406-bank-of-americaplus-4_5-on-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank of America +4.5% on Q4 beat</a></h4><ul><li>Bank of America (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>)<font color=\"green\"> advances 4.5%</font> in premarket trading after <a href=\"https://seekingalpha.com/pr/17381791-bank-america-reports-fourth-quarter-2018-financial-results\" target=\"_blank\">Q4 EPS </a>of 70 cents powers ahead of the consensus estimate of 63 cents, on strength of Consumer Banking and Global Wealth and Investment Management unit results along with cost controls.</li><li>Q4 revenue of $22.7B beats the average analyst estimate by $390M; increases from $20.4B a year ago.</li><li>Q4 provision for credit losses decreased by $96M to $905M, and net charge-off ratio fell to 0.39%.</li><li>Q4 efficiency ratio improved to 58% from 65% a year ago.</li><li>Consumer Banking net income rose 52% to $3.3B, while Global Wealth and Investment Management net income increased 43% to $1.1B.</li><li>In Global Markets, sales and trading revenue fell 6% to $2.5B, excluding net debit valuation adjustment gains of $52M; equities up 11% to $1.1B and FICC down 15% to $1.4B.</li><li>Return on average common shareholders' equity increased to 11.6% from 3.3% Y/Y.</li><li>Conference call at 8:00 AM ET; 1-877-200-4456 (US) Conference ID 79795.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3423378-bank-america-beats-0_07-beats-revenue\" target=\"_blank\">Bank of America beats by $0.07, beats on revenue</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3423406\" data-linked=\"Bank of America +4.5% on Q4 beat\" data-tweet=\"$BAC - Bank of America +4.5% on Q4 beat https://seekingalpha.com/news/3423406-bank-of-americaplus-4_5-on-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3423406-bank-of-americaplus-4_5-on-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423405\" data-ts=\"1547642367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423405-goldman-sachs-beats-1_74-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs beats by $1.74, beats on revenue</a></h4><ul><li>Goldman Sachs (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>): Q4 GAAP EPS of $6.04 <span style=\"color:green\">beats by $1.74</span>.</li><li>Revenue of $8.08B (-0.5% Y/Y) <font color=\"green\">beats by $580M</font>.</li><li>Shares <font color=\"green\">+1.02%</font> PM.</li><li><a href=\"https://www.goldmansachs.com/media-relations/press-releases/current/pdfs/2018-q4-results.pdf\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3423405\" data-linked=\"Goldman Sachs beats by $1.74, beats on revenue\" data-tweet=\"$GS - Goldman Sachs beats by $1.74, beats on revenue https://seekingalpha.com/news/3423405-goldman-sachs-beats-1_74-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3423405-goldman-sachs-beats-1_74-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423401\" data-ts=\"1547642051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423401-nordstromminus-9-bullish-analysts-capitulate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordstrom -9% as bullish analysts capitulate</a></h4><ul> <li>Atlantic Equities lowers Nordstrom (NYSE:<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>) to a Neutral rating after having the department store stock set at Overweight.</li> <li>The firm chops its price target on Nordstrom to $45 from $68.</li> <li>Telsey slides Nordstrom to Market Perform from Outperform, while Goldman Sachs moves to Neutral from Buy.</li><li>Shares of Nordstrom are <font color=\"red\">down 9.0%</font> in premarket trading after yesterday's <a href=\"https://seekingalpha.com/news/3423330-nordstrom-minus-2_8-percent-holiday-sales-guidance\" target=\"_blank\">report</a> from the company on holiday sales disappointed and profit guidance was cut.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423401\" data-linked=\"Nordstrom -9% as bullish analysts capitulate\" data-tweet=\"$JWN - Nordstrom -9% as bullish analysts capitulate https://seekingalpha.com/news/3423401-nordstromminus-9-bullish-analysts-capitulate?source=tweet\" data-url=\"https://seekingalpha.com/news/3423401-nordstromminus-9-bullish-analysts-capitulate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423400\" data-ts=\"1547641759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBIV\" target=\"_blank\">VBIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423400-oppenheimer-likes-vbi-vaccines-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer likes VBI Vaccines in premarket analyst action</a></h4><ul><li>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines'>VBIV</a>) initiated with Outperform rating and $9 (408% upside) price target at Oppenheimer. Shares up <font color=\"green\">16% </font>premarket.</li><li>ViewRay (NASDAQ:<a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a>) initiated with Buy rating and $13 (86% upside) price target at Guggenheim.</li><li>Incyte (NASDAQ:<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a>) downgraded to Neutral with an $82 (4% upside) price target at UBS. Shares down <font color=\"red\">1%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3423400\" data-linked=\"Oppenheimer likes VBI Vaccines in premarket analyst action\" data-tweet=\"$VBIV $VBIV $VRAY - Oppenheimer likes VBI Vaccines in premarket analyst action https://seekingalpha.com/news/3423400-oppenheimer-likes-vbi-vaccines-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3423400-oppenheimer-likes-vbi-vaccines-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423397\" data-ts=\"1547641601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FISV\" target=\"_blank\">FISV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423397-fiserv-down-2-after-preliminary-q4-and-fy18-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fiserv down 2% after preliminary Q4 and FY18 results</a></h4><ul> <li>Fiserv (NASDAQ:<a href='https://seekingalpha.com/symbol/FISV' title='Fiserv, Inc.'>FISV</a>) <a href=\"https://seekingalpha.com/pr/17381854-fiserv-announces-preliminary-fourth-quarter-full-year-2018-results-2019-outlook\" target=\"_blank\">reports</a> preliminary financial results for Q4 and FY 2018 and outlook for 2019.</li>          <li><strong>Preliminary Q4 and FY 2018 GAAP Results</strong></li>     <li>Q4 and FY Revenue of $1.55B and $5.82B, respectively.</li>     <li>Q4 and FY EPS is expected in       the range of $0.71 to $0.72 and $2.87 to $2.88, respectively.</li>     <li><strong>Preliminary Q4 and FY 2018 Non-GAAP Results</strong></li>     <li>Q4 and FY Revenue of $1.47B and $5.54B, respectively.</li>          <li>Q4 and FY EPS is expected in the range of $0.84 to       $0.85 and $3.10 to $3.11, respectively.</li>     <li><strong>Preliminary Outlook for 2019</strong></li>     <li>Fiserv expects internal revenue growth in a range of 4.5 to 5%.</li><li>Non-GAAP EPS is expected in the range of $3.39 to $3.52.</li>     <li>Agreement to Combine with First Data Corporation</li>     <li>Also, Fiserv will       combine with First Data Corporation in an all-stock transaction for an       equity value of ~$22B.</li><li>Actual Q4 and FY 2018 results are expected on February 7.</li><li>Shares are down <font color=\"red\">2%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3423397\" data-linked=\"Fiserv down 2% after preliminary Q4 and FY18 results\" data-tweet=\"$FISV - Fiserv down 2% after preliminary Q4 and FY18 results https://seekingalpha.com/news/3423397-fiserv-down-2-after-preliminary-q4-and-fy18-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3423397-fiserv-down-2-after-preliminary-q4-and-fy18-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423396\" data-ts=\"1547641246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDC\" target=\"_blank\">FDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423396-m-animal-spirits-hit-payments-fiserv-and-first-data-to-merge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">M&amp;A animal spirits hit payments - Fiserv and First Data to merge</a></h4><ul><li>The all-stock deal will have First Data (NYSE:<a href='https://seekingalpha.com/symbol/FDC' title='First Data Corporation'>FDC</a>) owners getting 0.303 Fiserv (NASDAQ:<a href='https://seekingalpha.com/symbol/FISV' title='Fiserv, Inc.'>FISV</a>) shares for each share of FDC they hold.</li><li>That's an equity value of $22.74B based on yesterday's closing prices, and a <font color=\"green\">29% premium</font> to the five-day weighted average price of FDC. After the close, Fiserv shareholders will own 57% of the combined company.</li><li>The merger is seen generating about $900M of run-rate expense savings, and at least $500M of revenue synergies. More than $4B of annual free cash flow is seen by year 3, and the deal is expected to be immediately accretive to adjusted EPS by more than 20%.</li><li>A <a href=\"http://fiserv.com\" target=\"_blank\">conference call</a> is set for 8:30 ET.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17381862-fiserv-combine-first-data-corporation-create-global-leader-payments-fintech\" target=\"_blank\">Press Release</a></li><li>FISV <font color=\"red\">-5.4%</font>, FDC <font color=\"green\">+17.4%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3423396\" data-linked=\"M&amp;A animal spirits hit payments - Fiserv and First Data to merge\" data-tweet=\"$FDC $FDC $FISV - M&amp;A animal spirits hit payments - Fiserv and First Data to merge https://seekingalpha.com/news/3423396-m-animal-spirits-hit-payments-fiserv-and-first-data-to-merge?source=tweet\" data-url=\"https://seekingalpha.com/news/3423396-m-animal-spirits-hit-payments-fiserv-and-first-data-to-merge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3423390\" data-ts=\"1547640901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CZR\" target=\"_blank\">CZR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3423390-baml-turns-cautious-on-caesars\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML turns cautious on Caesars</a></h4><ul> <li>Bank of America Merrill Lynch downgrades Caesars Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment'>CZR</a>) to a Neutral rating after having the casino stock slotted at Buy.</li> <li>\"Our core thesis of Las Vegas renovation upside is not materializing and we think regional marketing cuts may fade in 2019, while revenue faces rising competition in Atlantic City and promotions in IL and MS,\" warns analyst Shaun Kelly.</li> <li>\"CZR\u2019s free cash flow conversion and yield (even on a maintenance basis) is also well below peers,\" he notes.</li> <li>BAML keeps a price objective of $9 on Caesars.</li> <li>Shares of Caesars are <font color=\"red\">down 0.57%</font> in premarket trading to $8.70.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3423390\" data-linked=\"BAML turns cautious on Caesars\" data-tweet=\"$CZR - BAML turns cautious on Caesars https://seekingalpha.com/news/3423390-baml-turns-cautious-on-caesars?source=tweet\" data-url=\"https://seekingalpha.com/news/3423390-baml-turns-cautious-on-caesars\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":66,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}